WO2008011483A2 - Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds - Google Patents

Abstract

Disclosed herein are methods of treating a patient suffering from one or more types of chronic pain using compounds of the following formula (II) wherein the variables have the meaning defined in the specification.

Description

METHODS FOR TREATING CHRONIC PAiN USING 1 -ARYL-1 -HYDROXY-

2,3-DIAMINO-PROPYL AMINES, 1 -HETEROARYL-1 -HYDROXY-2,3-

DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention is directed to methods of treating a patient suffering from one or more types of chronic pain using derivatives of 1 -aryi-1 - hydroxy-2,3-diamino-propyl amines, 1 -heteroaryl-1 -hydroxy-2,3-diamino- propyl amines and related compounds. Background Art

1 -Phenyl-2-decanoylamino-3-morpholtno-1 -propanol (PDMP) was discovered by Vunam, R. R. and Radin, N., Chem, Phys. Lipids, 26, 265-278, 1980. Preparation of PDMP is described in Inokuchi, J. et ai., J. Lipid Res. 28, 565-571 , 1987; Radin, A. et ai., NeuroProtocois, 3(2), 145-55, 1993; Radin, A. et at., J. Lipid Res. 36, 611 -621 , 1995 and US 5916911.

POMP mixture of DL-erythro and DL- threo isomers

These derivatives inhibit glucosylceramide (GlcCer) formation by inhibiting the enzyme GlcCer synthase, thereby lowering the level of glycosphingolipids.) The isomers most active have the f?,R-(D-tf7reo)-configuration. Four enantiomers are produced during the synthesis. Because only the O-threo enantiomers are active in inhibiting the glucosylceramide synthase, resolution of the active D-threo inhibitors was performed bychiral chromatography. Moreover, D-threo-PDMP has antitumor activity via inhibition of glycosphingolipid biosynthesis as described by lnokuchi J., Cancer Letters 38(1 -2), 23-30, 1987.

L-threo-PDMP D-f/)reø-PDMP

Furthermore, it was also reported that D-threo-PDMP suppresses synaptic function by Mizutani A. et al., Biochem. Biophys. Res, Commun., 222, 494-498, 1996, Preparation of enantiomericaily pure D-threo-PDMP has been reported by Mitchell, Scott A.[ J. Org, Chem., 63 (24), 8837-8842, 1998]; Miura, T. et at, [Bioorg. Med. Chem., 6, 1481 -1498, 1998]; Shin, S. et al., [Tetrahedron asymmetry, 11 , 3293-3301 , 2000]; VVO 2002012185

L-f/ireoPDMP is an agent for treating neuronal diseases WO 95/05177. This compound is also described to be an agent for protecting brain in US 6407064. Moreover treatment with L-threo-PDMP after transient forebrain ischemia in rats ameliorated the deficit of a well learned spatial memory by an 8-arm maze task, suggesting a potential for neurodegenerative disorders as described by lnokuchi et al., Ann. N. Y. Acad. ScL, 845(1 ), 219- 224, 1998 and JP 10324671 (Seikagaku Kogyo Co.).

A stereoselective synthesis of enantiomericaily pure D-threo-PDMP has also been described by Shin, S. et al., Tetrahedron asymmetry, 11 , 3293- 3301 , 2000 and WO 2002012185 the key step is the regioselective cleavage by nitrogen nucleophiles, as morpholine, of the C(3)-N-bond of non-activated enantiomericaily pure aziridine-2-methanoIs.

99 % D-threo-PDMP 81 % ι) TMS-I, CH₃CN ii) a) morpholine t) HCI MI) Pd(OH)₂ H₂ AcOH, MeOH, 40³C ιv)10% NaOH, dacanoyl chioride 81%

On the other hand, the synthesis of enantiomerically pure (1 S,2S)-1 -phenyl-2- decanoylamino-3-morpholino-1 -propanol (L-threo-PDMP) from L-serine has also been described by Mitchell, Scott A., J. Org. Chem., 63 (24), 8837-8842, 1998.

O'Donnei SChiff base

I) IBU₅AI₂H II) PhMgBr L-f/ireo-PDMP

Other known methods to obtain L-threo-PDMP are described by Miura, T. et al, Bioorg. Med Chem., 6, 1481 -1498, 1998 and in JP-A-9-216858. L-f/ireo-PDMP is an agent for treating neuronal diseases WO 95/05177. This compound is also described to be an agent for protecting brain in US 6407064. Moreover treatment with L-tf?reσ-PDMP after transient forebrain ischemia in rats ameliorated the deficit of a well learned spatial memory by an 8-arm maze task, suggesting a potential for neurodegenerative disorders as described by lnokuchi et al., Ann. N. Y. Acad. ScL, 845(1 ), 219-224, 1998 and JP 10324671 (Seikagaku Kogyo Co.),

Synthesis of (1 S,2S)- threo- and (1 fl,2S)-e/yf/7rø-1 -phenyl-2- palmitoyiamino-3-Λ/-morpho!ino-1 -propanol (PPMP) were described starting from Garner aldehyde of L-serine, by Nishida, A., Synlett, 4, 389-390, 1998.

L-f/?reoPPMP D-erythro-PPMP

Compounds with longer chain fatty acyl groups (than decanoyl) have been found to be substancially more effective as inhibitor of GCS. D-fftreo-1 - phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol (P4 or PPPP) analogues were first obtained by a Mannich reaction as described Abe, A. et al., J. Biochem., 1 11 , 191 -196, 1992 or US 5916911 and WO 2001004108.

O-threoPA

Preparation of D-tf?reø-4'-hydroxy-P4, one of the most potent inhibitor of 10 GCS, was described by Lee, L et al., J. Biol. Chem., 27 A, 21 , 14662-14669, 1999. In addition, a series of dioxane substitutions was designed and tested. These included 3\4'-methyienedioxypheny!-3',4'- ethylenedioxyphenyl-, and 3',4'-trimethy!enedioxyphenyI-substituted homologues.

, r D-?/ireo-4'-hydroxy-P4

Synthesis of enantiomerically pure D-tf?reo-1 -pheny!-2- benzyioxycarbonylamino-3-pyrrolidino-1 -propanol (PBPP) and D-threo-P4 and its analogues from Λ/-benzyloxycarbonyl-D-serine, was described by Jimbo M. 0 et al, J. Biochem., 127(3), 485-91 , 2000 and EP 782992 (Seikagaku Kogyo Co.). PBPP is described as a potent GCS inhibitor.

D-threo-PBPP

Novel prodrugs of P4 derivatives were described in US 20020198240 and WO 2002062777,

Synthesis of enantiomericaliy pure of D-tf?reoethylenedioxy-P4 and D- #7røo-p-nnethoxy-P4 were described by Husain A, and Ganem B., Tetrahedron Lett, 43. 8621 -8623, 2002. The key step is a highly syn-selective additions of aryl Grignard reagents to Garner aldehyde.

Garner Aldehyde m)

D ff>reo-ethylenedioxy-P4 ι) 3,4-ethylenβdιoxypheπylmagnesιum bromide, 78^CC CuI THF Me₂S 64 % n) 0 1 N HC!, THF 82%, MsCI Et₃N DCM O¹¹C 85 % in) pyrrolidine, DMF, 45°C 58 % ιv) 3 N HCI, O¹¹C, to RT then Ci₅H₃₁COCI, Et₃N DMAP, DCM -20°C, 87% Dtastereoselective synthesis of PA analogues were described in US 03/0153768 and WO 2003045928 (Genzyme Corp.); Oxazolines I [R1 = (un)substituted aryl; R², R³ = H, (un)substituted aliphatic; NR²R³ = heterocyclic] are prepared as intermediates for P4 glucosyltransferase inhibitors from R¹CHO and R²R³NCOCH₂CN. Thus, methyl isocyanoacetate CNCH₂CO₂Me was treated with pyrrolidine and the amide was treated with 1 ,4-benzodioxane-θ-carboxaldehyde, followed by hydrolysis of the oxazoline using HCI in methanol, reduction of the keto group of amide Il using LiAIH₄, and acylation with palmitoyl chloride to give D,L-tf?reoethylenedioxy-P4 111.

D,L-tf?reo-3',4'-ethylenedιoxy-P4

Synthesis of enantiopure P4 analogues were described in WO 2003008399 (Genzyme Corp.).

P4 derivatives, such as I [R¹, R⁵ = un(substituted) aromatic; R², R³ = H, un(substituted) aliphatic; NR²R³ = (un)substituted non-aromatic heterocyclic ring; R⁴ = O, H₂], were prepared for their therapeutic use as GCS inhibitors. Thus, D~tf?reo-ethylenedioxy-P4 was prepared via a multistep synthetic sequence starting from S-(+)-Ph giycinol, phenyl-α-bromoacetate, 1 ,4- benzodioxan-6-carboxaldehyde, pyrrolidine and palmitoyl chloride.

D- threo3' , 4'-ethy I e nedsoxy ~ P4

New D-threo-PΛ analogues that bear ether substituents on the aromatic ring have been recently synthesized from D-serine and found to suppress neurite extension in an embryonic insect cell line as described by Slavish., J. P. etai., Bioorg, Med. Chem, Lett,, 14, 1487-1490, 2004. Further references which serve as background to the present invention are United States Patent Nos. 5.945,442; 5,952,370; 6,030,995 and 6,051 ,598; Journal of Labelled Compounds & Radiopharmaceuticals (1996), 38(3), 285-97; Published PCT application WO 01/38228; and Kastron et al. Latvijas PSR Zinatnu Akademijas Vestis, Kimijas Serija (1965) (4), 474-7.

SUMMARY OF THE INVENTION

The present invention is directed to methods of treating a patient suffering from one or more types of chronic pain using compounds of Formula 1 :

Formula 2 where Ri is H or alkyl of 1 to 6 carbons, R₂ is H, alkyl of 1 to 6 carbons or the Ri and R₂ groups together with the nitrogen form a saturated or unsaturated 4, 5, 6 or 7 membered ring that optionally includes one or two heteroatoms independently selected from N, O and S, said 4, 5, 6 or 7 membered ring optionally being substituted with a halogen, COOH, CH₂OH, OH, B(OH)₂, cyano or with an alkyl group having 1 to 6 alkyl groups;

R₃ is independently selected from H, alkyl of 1 to 20 carbons, ary! or heteroaryl, aryl-alkyl or heteroaryl-alkyl where the alkyl moiety is has 1 to 4 carbons, cycloalkyi of 3 to 6 carbons, said aryl or heteroaryl groups being optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, alkyi of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 6 carbons, or

R₃ is CO-R₇ or CO-O-R₇ where R₇ is H, alkyl of 1 to 1 to 20 carbons, benzyl, alkyl of 1 to 20 carbons substituted with and NH₂ group, with a NHCOOalkyI or with an NH-COalkyl group where the alkyl group has one to 6 carbons, or R₇ is aryl, heteroaryl, aryl-alkyi or heteroaryl-alkyl where the alkyl moiety is branched or unbranched and has 1 to 4 carbons, said aryl or heteroaryl groups being optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 6 carbons;

R₄ is H, aikyl of 1 to 6 carbons or CO-R₈ where R₈ is aikyl of 1 to 6 carbons; the wavy lines represent bonds connected to carbons having R or S configuration, and Rio is selected from the groups of formulas (i) and (ii)

(i) (ii) where the ^* indicates the carbon atom to which the remaining moiety of the molecule is attached;

R₅ and R₆ independently are H, alkyl of 1 to 6 carbons, halogen, alkoxy of 1 to 6 carbons or the R₅ and R₆ groups together with the atoms to which they are attached jointly form a carbocycϋc or a heterocyclic ring, the carbocyclic ring having 5 or 6 atoms in the ring, the heterocyclic ring having 5 or 6 atoms in the ring and 1 to 3 heteroatoms independently selected from N, O and S₁ and said carbocyclic or heterocyclic ring jointly formed by R₅ and R₆ being optionally substituted with 1 to 6 Rg groups where R₉ is independently selected from halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, with the proviso: that when Ri₀ has formula (ii) then Formula 1 does not include compounds where R₄ is hydrogen and Ri and R₂ jointly with the nitrogen form a morphoiin or a pyrrolidin ring and where R₅ and Re both are H or one of R₅ and R₆ is OCH₃ and the other is H, and the present invention is also directed to all pharmaceutically acceptable salts of said compounds.

DETAILED DESCRIPTION OF THE INVENTION A general description of the compounds of the invention is provided in the Summary Section of the present application for patent. Most compounds of the invention contain one or more asymmetric centers, such that the compounds may exist in enantiomeric as well as in diastereomeric forms, in fact, most of the compounds of the present invention have two asymmetric carbons adjacent to one another and therefore can exist in erythro or threo form, with each of these two forms having dextrorotatory (D) or levorotary (L) enantiomers. Although the threo form is generally preferred in accordance with the present invention for analgesic activity, unless it is specifically noted otherwise, the scope of the present invention includes all enantiomers, diastereomers and diastereomeric and racemic mixtures. In light of the foregoing, it should be clearly understood that the designation "DL" or "(+/-)" or " (±)" in this application includes the pure dextrorotatory enantiomer, the pure levorotatory enantiomer and all racemic mixtures, including mixtures where the two enantiomers are present in equal or in unequal proportions. Moreover, for simplicity sake in many of the structural formulas, such as in the example below, only one of the enantiomers is actually shown but when the designation "DL" (or "(+/-)" or "(±)") appears it also includes the enantiomeric form (mirror image) of the structure actually shown in the formula. For Example;

OH

H^ ISIH₂ ^~J DL- threo or ±- threo Thus, in the example above, only one enantiomer is shown, but because the designation "DL" (or "(+A)" or "(±)") appears below the formula, its optical isomer

and all racemic mixtures of the two optical isomers are also included.

In the case of some compounds of the present invention one enantiomer of the threo, and in some cases of the erythro, is significantly more active as an analgesic than the other enantiomer of the same pair.

Some of the compounds which may be used in the method of the present invention may contain three or more asymmetric centers.

Keeping the foregoing examples in mind a person of ordinary skill in the art should readily understand the scope of each described example, although in a broad sense all isomers, enantiomers and racemic mixtures are within the scope of the invention.

The term "alkyi" in the general description and definition of the compounds includes straight chain as well as branch-chained alkyl groups. Generally speaking the compounds of the invention may form salts with pharmaceutically acceptable acids or bases, and such pharmaceutically acceptable salts of the compounds of Formula 1 are also within the scope of the invention.

Referring now to the novel compounds of Formula 1 , the Rs and Re groups preferably both are independently selected from H, alkyl, alkoxy and still more preferably are H. In the preferred compounds the R₃ groups are preferably both H, or one of the R₃ groups is H and the other is an acyl group or an arylalkylcarbamoyl group. The R₄ group is preferably H (but see the "proviso" in the Summary section) or alkanoyl, and the Ri and R₂ groups preferably are pyrrolidino or morpholino.

The presently most preferred novel compounds of the invention are disclosed with their structural formulas in the ensuing Table and or description, showing activity of exemplary compounds relevant to their ability to act as analgesics.

BIOLOGICAL ACTIVITY, MODES OF ADMINISTRATION The compounds described here may be used to treat a patient suffering from one or more types of chronic pain, including neuropathic pain, inflammatory pain, headache pain, somatic pain, visceral pain, and referred pain.

To "treat," as used here, means to dea! with medically. It includes, for example, administering a compound of the invention to prevent a pain, to alleviate its severity, and to prevent its reoccurance. The term "pain," as used here, means any unpleasant sensory experience, usually associated with a physical disorder. The physical disorder may or may not be apparent to a clinician. Pain is of two types: chronic and acute. An "acute pain" is a pain of short duration having a sudden onset. One type of acute pain, for example, is cutaneous pain felt on injury to the skin or other superficial tissues, such as caused by a cut or a burn. Cutaneous nociceptors terminate just below the skin, and due to the high concentration of nerve endings, produce a well-defined, localized pain of short duration. "Chronic pain" is a pain other than an acute pain. Chronic pain includes neuropathic pain, inflammatory pain, headache pain, somatic pain visceral pain and referred pain.

/. Neuropathic Pain

The compounds of the invention may be used to treat pain caused by or otherwise associated with any of the following neuropathic pain conditions. "Neuropathic pain" means abnormal sensory input, resulting in discomfort, from the peripheral nervous system, central nervous systems, or both. A. Symptoms of neuropathic pain

Symptoms of neuropathic pain can involve persistent, spontaneous pain, as well as allodynia (a painful response to a stimulus that normally is not painful), hyperalgesia (an accentuated response to a painful stimulus that usually causes only a miid discomfort, such as a pin prick), or hyperpathia (where a short discomfort becomes a prolonged severe pain).

B. Causes of neuropathic pain

Neuropathic pain may be caused by any of the following.

1. A traumatic insult, such as, for example, a nerve compression injury (e.g., a nerve crush, a nerve stretch, a nerve entrapment or an incomplete nerve transsection); a spinal cord injury (e.g., a hemisection of the spinal cord); a limb amputation; a contusion; an inflammation (e.g., an inflammation of the spinal cord); or a surgical procedure.

2. An ischemic event, including, for example, a stroke and heart attack. 3. An infectious agent

4. Exposure to a toxin, including, for example, a drug, an alcohol, a heavy meta! (e.g., lead, arsenic, mercury), an industrial agent (e.g., a solvent, fumes from a glue) or nitrous oxide.

5, A disease, including, for example, an inflammatory disorder, a neoplastic tumor, an acquired immune deficiency syndrome (AIDS), Lymes disease, a leprosy, a metabolic disease, a neurodegenerative disease, a spinal stenosis, a mononeuropathy, a polyneuropathy, and a peripheral nerve disorder, such as a neuroma.

C. Types of neuropathic pain 1. Neuralgia.

A neuralgia is a pain that radiates along the course of one or more specific nerves usually without any demonstrable pathological change in the nerve structure. The causes of neuralgia are varied. Chemical irritation, inflammation, trauma (including surgery), compression by nearby structures (for instance, tumors), and infections may all lead to neuralgia. In many cases, however, the cause is unknown or unidentifiable. Neuralgia is most common in elderiy persons, but it may occur at any age. A neuralgia, includes, without limitation, a trigeminal neuralgia, a spinal stenosis, a post-herpetic neuralgia, a postherpetic neuralgia, a glossopharyngeal neuralgia, pain associated with nerve entrapment disorders, a sciatica and an atypical facial pain. Neuralgia is a painful disorder of the cranial nerves. Falling under the category of neuralgia are trigeminal neuralgia (TN), atypical facial pain, and postherpetic neuralgia (caused by shingles or herpes). The affected nerves are responsible for sensing touch, temperature and pressure in the facial area from the jaw to the forehead. The disorder generally causes short episodes of excruciating pain, usually for less than two minutes and on only one side of the face. The pain can be described in a variety of ways such as "stabbing," "sharp," "like lightning," "burning," and even "itchy", In the atypical form of TN, the pain can also present as severe or merely aching and last for extended periods. The pain associated with TN is recognized as one the most excruciating pains that can be experienced.

Simple stimuli such as eating, talking, washing the face, or any light touch or sensation can trigger an attack (even the sensation of a gentle breeze). The attacks can occur in clusters or as an isolated attack.

Symptoms include sharp, stabbing pain or constant, burning pain located anywhere, usually on or near the surface of the body, in the same location for each episode; pain along the path of a specific nerve; impaired function of affected body part due to pain, or muscle weakness due to concomitant motor nerve damage; increased sensitivity of the skin or numbness of the affected skin area (feeling similar to a local anesthetic such as a Novacaine shot); and any touch or pressure is interpreted as pain. Movement may also be painful.

Trigeminal neuralgia is the most common form of neuralgia. It affects the main sensory nerve of the face, the trigeminal nerve ("trigeminal" literally means "three origins", referring to the division of the nerve into 3 branches). This condition involves sudden and short attacks of severe pain on the side of the face, along the area supplied by the trigeminal nerve on that side. The pain attacks may be severe enough to cause a facial grimace, which is classically referred to as a painful tic (tic douloureux). Sometimes, the cause of trigeminal neuralgia is a blood vessel or small tumor pressing on the nerve. Disorders such as multiple sclerosis (an inflammatory disease affecting the brain and spinal cord), certain forms of arthritis, and diabetes (high blood sugar) may also cause trigeminal neuralgia, but a cause is not always identified, in this condition, certain movements such as chewing, talking, swallowing, or touching an area of the face may trigger a spasm of excruciating pain. A related but rather uncommon neuralgia affects the giosso-pharyngeal nerve, which provides sensation to the throat. Symptoms of this neuralgia are short, shock-like episodes of pain located in the throat.

Neuralgia may occur after infections such as shingles, which is caused by the varicella-zoster virus, a type of herpesvirus. This neuralgia produces a constant burning pain after the shingles rash has healed. The pain is worsened by movement of or contact with the affected area. Not all of those diagnosed with shingles go on to experience postherpetic neuralgia, which can be more painful than shingles. The pain and sensitivity can last for months or even years. The pain is usually in the form of an intolerable sensitivity to any touch but especially light touch. Postherpetic neuralgia is not restricted to the face; it can occur anywhere on the body but usually occurs at the location of the shingles rash. Depression is not uncommon due to the pain and social isolation during the illness.

Postherpetic neuralgia may be debilitating long after signs of the original herpes infection have disappeared. Other infectious diseases that may cause neuralgia are syphilis and Lyme disease.

Diabetes is another common cause of neuralgia. This very common medical problem affects almost 1 out of every 20 Americans during adulthood. Diabetes damages the tiny arteries that supply circulation to the nerves, resulting in nerve fiber malfunction and sometimes nerve loss. Diabetes can produce almost any neuralgia, including trigeminal neuralgia, carpal tunnel syndrome (pain and numbness of the hand and wrist), and meralgia paresthetica (numbness and pain in the thigh due to damage to the lateral femoral cutaneous nerve). Strict control of blood sugar may prevent diabetic nerve damage and may accelerate recovery in patients who do develop neuralgia.

Other medical conditions that may be associated with neuralgias are chronic renal insufficiency and porphyria -- a hereditary disease in which the body cannot rid itself of certain substances produced after the normal breakdown of blood in the body. Certain drugs may also cause this problem, 2. Deafferentation.

Deafferentation indicates a loss of the sensory input from a portion of the body, and can be caused by interruption of either peripheral sensory fibres or nerves from the central nervous system. A deafferentation pain syndrome, includes, without limitation, an injury to the brain or spinal cord, a post-stroke pain, a phantom pain, a paraplegia, a brachial plexus avulsion injuries, lumbar radiculopathies.

3. Complex regional pain syndromes (CRPSs)

CRPS is a chronic pain syndrome with two forms. CRPS 1 currently replaces the term "reflex sympathetic dystrophy syndrome". It is a chronic nerve disorder that occurs most often in the arms or legs after a minor or major injury. CRPS 1 is associated with severe pain; changes in the nails, bone, and skin; and an increased sensitivity to touch in the affected limb. CRPS 2 replaces the term causalgia, and results from an identified injury to the nerve. A CRPS, includes, without limitation, a CRPS Type I (reflex sympathetic dystrophy) and a CRPS Type Il (causalgia).

4. Neuropathy.

A neuropathy is a functional or pathological change in a nerve and is characterized clinically by sensory or motor neuron abnormalities.

Central neuropathy is a functional or pathological change in the central nervous system. Peripheral neuropathy is a functional or pathological change in one or more peripheral nerves. The peripheral nerves relay information from your central nervous system (brain and spinal cord) to muscles and other organs and from your skin, joints, and other organs back to your brain. Peripheral neuropathy occurs when these nerves fail to carry information to and from the brain and spinal cord, resulting in pain, loss of sensation, or inability to control muscles. In some cases, the failure of nerves that control blood vessels, intestines, and other organs results in abnormal blood pressure, digestion problems, and loss of other basic body processes. Risk factors for neuropathy include diabetes, heavy alcohol use, and exposure to certain chemicals and drugs. Some people have a hereditary predisposition for neuropathy. Prolonged pressure on a nerve is another risk for developing a nerve injury. Pressure injury may be caused by prolonged immobility (such as a long surgical procedure or lengthy illness) or compression of a nerve by casts, splints, braces, crutches, or other devices. Polyneuropathy implies a widespread process that usually affects both sides of the body equally. The symptoms depend on which type of nerve is affected. The three main types of nerves are sensory, motor, and autonomic. Neuropathy can affect any one or a combination of all three types of nerves. Symptoms also depend on whether the condition affects the whole body or just one nerve (as from an injury). The cause of chronic inflammatory polyneuropathy is an abnormal immune response. The specific antigens, immune processes, and triggering factors are variable and in many cases are unknown. It may occur in association with other conditions such as HIV, inflammatory bowel disease, lupus erythematosis, chronic active hepatitis, and blood cell abnormalities.

Peripheral neuropathy may involve a function or pathological change to a single nerve or nerve group (monneuropathy) or a function or pathological change affecting multiple nerves (polyneuropathy). Peripheral neuropathies Hereditary disorders

Charcot-Marie-Tooth disease

Friedreich's ataxia Systemic or metabolic disorders

Diabetes {diabetic neuropathy )

Dietary deficiencies (especially vitamin B-12)

Excessive alcohoi use (alcoholic neuropathy )

Uremia (from kidney failure ) Cancer (including bone cancer and other cancers)

Infectious or inflammatory conditions

AIDS

Hepatitis

Colorado tick fever Diphtheria

Gutliain-Barre syndrome

HIV infection without development of AIDS

Leprosy

Lyme disease Polyarteritis nodosa

Rheumatoid arthritis

Sarcoidosis

Sjogren's syndrome

Syphilis Systemic Lupus erythematosus amyloid Exposure to toxic compounds

Sniffing glue or other toxic compounds

Nitrous oxide Industrial agents - especially solvents

Heavy metals (lead, arsenic, mercury, etc.) Neuropathy secondary to drugs like analgesic nephropathy

Rhabdomyolysis

Macrohagic myofascitis

Highly Active Anti-Retrviral Therapy (HAART)-induced neuropathy Chemotherapy Incuced Neuropathy Miscellaneous causes

Ischemia (decreased oxygen/decreased blood flow)

Prolonged exposure to cold temperature a. Polyneuropathy Polyneuropathy is a peripheral neuropathy involving the loss of movement or sensation to an area caused by damage or destruction to multiple peripheral nerves. Polyneuropathic pain, includes, without limitation, post-polio syndrome, postmastectomy syndrome, diabetic neuropathy, alcohol neuropathy, amyloidosis, toxin exposure, AIDS, hypothyroidism, uremia, vitamin deficiencies, chemotherapy-induced pain, 2',3¹-didexoycytϊdine (ddC) treatment, exposure to the anticonvulsant phenytoin, exposure to antibiotics including chloramphenicol, nitrofurantoin and sulfonamineds, exposure to sedatives including barbital and hexobarbital, Guiilain-Barre syndrome, Fabry's disease or polyneuropathy secondary to cancers such as multiple myeloma. b. Mononeuropathy

Mononeuropathy is a peripheral neuropathy invoiving loss of movement or sensation to an area caused by damage or destruction to a single peripheral nerve or nerve group. Mononeuropathy is most often caused by damage to a local area resulting from injury or trauma, although occasionally systemic disorders may cause isolated nerve damage (as with mononeuritis multiplex). The usual causes are direct trauma, prolonged pressure on the nerve, and compression of the nerve by swelling or injury to nearby body structures. The damage includes destruction of the myelin sheath (covering) of the nerve or of part of the nerve cell (the axon). This damage slows or prevents conduction of impulses through the nerve. Mononeuropathy may involve any part of the body. Mononeuropathic pain, includes, without limitation, a sciatic nerve dysfunction, a common peroneal nerve dysfunction, a radial nerve dysfunction, an ulnar nerve dysfunction, a cranial mononeuropathy Vl, a cranial mononeuropathy VII, a cranial mononeuropathy III (compression type), a cranial mononeuropathy III (diabetic type), an axillary nerve dysfunction, a carpal tunnel syndrome, a femoral nerve dysfunction, a tibial nerve dysfunction, a Bell's palsy, a thoracic outlet syndrome, a carpal tunnel syndrome, and a sixth (abducent) nerve palsy. c. Generalized peripheral neuropathies

Generalized peripheral neuropathis are symmetrical, and usually due to various systematic ilinesses and disease processes that affect the peripheral nervous system in its entirety. They are further subdivided into several categories: i. Distal axonopathies are the result of some metabolic or toxic derangement of neurons. They may be caused by metabolic diseases such as diabetes, renal failure, deficiency syndromes such as malnutrition and alcoholism, or the effects of toxins or drugs. Distal axonopathy (aka dying back neuropathy) is a type of peripheral neuropathy that results from some metabolic or toxic derangement of peripheral nervous system (PNS) neurons. It is the most common response of nerves to metabolic or toxic disturbances, and as such may be caused by metabolic diseases such as diabetes, renal failure, deficiency syndromes such as malnutrition and alcoholism, or the effects of toxins or drugs. The most common cause of distal axonopathy is diabetes, and the most common distal axonopathy is diabetic neuropathy. ii. Myelinopathies are due to a primary attack on myelin causing an acute failure of impulse conduction. The most common cause is acute inflammatory demyelinating polyneuropathy (AIDP; aka Guillain-Barre syndrome), though other causes include chronic inflammatory demyelinating syndrome (CIDP), genetic metabolic disorders (e.g., leukodystrophy), or toxins. Myelinopathy is due to primary destruction of myelin or the myelinating Schwann cells, which leaves the axon intact, but causes an acute failure of impulse conduction. This demyelination slows clown or completely blocks the conduction of electicai impulses through the nerve. The most common cause is acute inflammatory demyelinating polyneuropathy (AIDP, better known as Guiilain-Barre syndrome), though other causes include chronic inflammatory demyelinating polyneuropathy (CIDP), genetic metabolic disorders (e.g., leukodystrophy or Charcot-Marie-Tooth disease), or toxins. iii, Neuronopathies are the result of destruction of peripheral nervous system (PNS) neurons. They may be caused by motor neurone diseases, sensory neuronopathies (e.g., Herpes zoster), toxins or autonomic dysfunction. Neurotoxins may cause neuronopathies, such as the chemotherapy agent vincristine. Neuronopathy is dysfunction due to damage to neurons of the peripheral nervous system (PNS), resulting in a peripheral neuropathy. It may be caused by motor neurone diseases, sensory neuronopathies (e.g., Herpes zoster), toxic substances or autonomic dysfunction, A person with neuronopathy may present in different ways, depending on the cause, the way it affects the nerve cells, and the type of nerve cell that is most affected. iv. Focal entrapment neuropathies (e.g., carpal tunnel syndrome) represent an additional category of generalized peripheral neuropathies.

//. Inflammatory pain

The compounds of the invention may be used to treat pain caused by or otherwise associated with any of the following inflammatory conditions. A. Arthritic disorder Arthritic disorders include, for example, a rheumatoid arthritis; a juvenile rheumatoid arthritis; a systemic lupus erythematosus (SLE); a gouty arthritis; a scleroderma; an osteoarthritis; a psoriatic arthritis; an ankylosing spondylitis; a Reiter's syndrome (reactive arthritis); an adult Still's disease; an arthritis from a viral infection; an arthritis from a bacterial infection, such as, e.g., a gonococcal arthritis and a non-gonococcal bacterial arthritis (septic arthritis); a Tertiary Lyme disease; a tuberculous arthritis; and an arthritis from a fungal infection, such as, e,g,, a blastomycosis B. Autoimmune diseases

Autoimmune diseases include, for example, a Guillatn-Barre syndrome, a Hashimoto's thyroiditis, a pernicious anemia, an Addison's disease, a type I diabetes, a systemic lupus erythematosus, a dermatomyositis, Sjogren's syndrome, a lupus erythematosus, a multiple sclerosis, a myasthenia gravis, a Reiter's syndrome, a Grave's disease, and a rheumatoid arthritis. C.

Connective tissue disorder Connective tissue disorders include, for example, a spondyloarthritis a dermatomyositis, and a fibromyalgia syndrome . D. Injury

Inflammation caused by injury, including, for example, a crush, puncture, stretch of a tissue or joint, may cause chronic inflammatory pain. E. Infection

Inflammation caused by infection, including, for example, a tuberculosis or an interstitial keratitis may cause chronic inflammatory pain. Infection may also result in inflammatory bowel diseases and irritable bowel syndromes. F. Neuritis Neuritis is an inflammatory process affecting a nerve or group of nerves. Symptoms depend on the nerves involved, but may include pain, paresthesias, paresis, or hypesthesia (numbness). Examples include: a. Brachial neuritis b. Retrobulbar neuropathy, an inflammatory process affecting the part of the optic nerve lying immediateiy behind the eyeball. c. Optic neuropathy, an inflammatory process affecting the optic nerve causing sudden, reduced vision in the affected eye. The cause of optic neuritis is unknown. The sudden inflammation of the optic nerve (the nerve connecting the eye and the brain) leads to swelling and destruction of the myelin sheath, The inflammation may occasionally be the result of a viral infection, or it may be caused by autoimmune diseases such as multiple sclerosis. Risk factors are related to the possible causes. d. Vestibular neuritis, a viral infection causing an inflammatory process affecting the vestibular nerve. G. Joint inflammation

Inflammation of the joint, such as that caused by bursitis or tendonitis, for example, may cause chronic inflammatory pain,

///. Headache Pain

The compounds of the invention may be used to treat pain caused by or otherwise associated with any of the following headache conditions. A headache (medically known as cephalgia) is a condition of mild to severe pain in the head; sometimes neck or upper back pain may also be interpreted as a headache. It may indicate an underlying local or systemic disease or be a disorder in itself. A. Muscular/myogenic headache

Muscular/myogenic headaches appear to involve the tightening or tensing of facial and neck muscles; they may radiate to the forehead. Tension headache is the most common form of myogenic headache.

A tension headache is a condition involving pain or discomfort in the head, scaip, or neck, usually associated with muscle tightness in these areas. Tension headaches result from the contraction of neck and scalp muscles. One cause of this muscle contraction is a response to stress, depression or anxiety. Any activity that causes the head to be held in one position for a long time without moving can cause a headache. Such activities include typing or use of computers, fine work with the hands, and use of a microscope.

Sleeping in a cold room or sleeping with the neck in an abnormal position may also trigger this type of headache. A tension-type headache, includes, without limitation, an episodic tension headache and a chronic tension headache. B. Vascular headache

The most common type of vascular headache is migraine. Other kinds of vascular headaches include cluster headaches, which cause repeated episodes of intense pain, and headaches resulting from high blood pressure 1. Migraine

A migraine is a heterogeneous disorder that generally involves recurring headaches. Migraines are different from other headaches because they occur with other symptoms, such as, e.g., nausea, vomiting, or sensitivity to light. In most people, a throbbing pain is felt only on one side of the head. Clinical features such as type of aura symptoms, presence of prodromes, or associated symptoms such as vertigo, may be seen in subgroups of patients with different underlying pathophysiological and genetic mechanisms. A migraine headache, includes, without limitation, a migraine without aura (common migraine), a migraine with aura (classic migraine), a menstrua! migraine, a migraine equivalent (acephalic headache), a complicated migraine, an abdominal migraine and a mixed tension migraine.

2. Cluster headache

Cluster headaches affect one side of the head (unilateral) and may be associated with tearing of the eyes and nasal congestion. They occurs in clusters, happening repeatedly every day at the same time for several weeks and then remitting,

D. High blood pressure headache

E. Traction and inflammatory headache

Traction and inflammatory headaches are usually symptoms of other disorders, ranging from stroke to sinus infection.

F. Hormone headache

G. Rebound headache

Rebound headaches, also known as medication overuse headaches, occur when medication is taken too frequently to relieve headache. Rebound headaches frequently occur daϋy and can be very painful, H. Chronic sinusitis headache Sinusitis is inflammation, either bacterial, fungal, viral, allergic or autoimmune, of the paranasal sinuses. Chronic sinusitis is one of the most common complications of the common cold. Symptoms include: Nasal congestion; facial pain; headache; fever; general malaise; thick green or yellow discharge; feeling of facial 'fullness⁵ worsening on bending over. In a small number of cases, chronic maxillary sinusitis can also be brought on by the spreading of bacteria from a dental infection. Chronic hyperplastic eosinophilic sinusitis is a noninfective form of chronic sinusitis. I. An organic headache J. lctal headaches lcta! headaches are headaches associated with seizure activity.

IV. Somatic pain

The compounds of the invention may be used to treat pain caused by or otherwise associated with any of the following somatic pain conditions. Somatic pain originates from ligaments, tendons, bones, blood vessels, and even nerves themselves, it is detected with somatic nociceptors. The scarcity of pain receptors in these areas produces a dull, poorly-localized pain of longer duration than cutaneous pain; examples include sprains and broken bones. Additional examples include the following. A. Excessive muscle tension

Excessive muclse tension can be caused, for example, by a sprain or a strain.

B. Repetitive motion disorders

Repetitive motion disorders can result from overuse of the hands, wrists, elbows, shoulders, neck, back, hips, knees, feet, legs, or ankles.

C. Muscle disorders

Muscle disorders causing somatic pain include, for example, a polymyositis, a dermatomyositis, a lupus, a fibromyalgia, a polymyalgia rheumatica, a macrophagic myofasciitis, and a rhabdomyolysis. Muscle pain can also be secondary to neurological and neuromuscular disorders including without limitation Parkinson's disease, Huntington's chorea, dystonias, tardive dyskinesias, drug-induced dyskinesias and dystonias, dyskinesias (paroxysmai), amyotrophic lateral sclerosis, multiple sclerosis, myoclonus, progressive supranuclear palsy, corttcobasal degeneration, choreoathetosis, spasticity, Wilson disease, multiple system atrophy (including Shy-Drager syndrome, striatonigral degeneration and olivopontocerebellar atrophy), and hereditary spastic paraplegia (including familial spastic paraparesis, familial spastic paraplegia, hereditary spastic paraparesis, Strumpell-Lorraine syndrome, and Strumpell's disease).

D. Myalgia Myalgia is muscle pain and is a symptom of many diseases and disorders. The most common cause for myalgia is either overuse or overstretching of a muscle or group of muscles. Myalgia without a traumatic history is often due to viral infections. Longer-term myalgias may be indicative of a metabolic myopathy, some nutritional deficiencies or chronic fatigue syndrome.

E. Infection

Infection can cause somatic pain. Examples of such infection include, for example, an abscess in the muscle, a trichinosis, an influenza, a Lyme disease, a malaria, a Rocky Mountain spotted fever, Avian influenza, the common cold, community-acquired pneumonia, meningitis, monkeypox, Severe Acute Respiratory Syndrome, toxic shock syndrome, trichinosis, typhoid fever, and upper respiratory tract infection.

F. Drugs

Drugs can cause somatic pain. Such drugs include, for example, cocaine, statins for lowering cholesterol (such as atorvastatin, simvastatin, and lovastatin), and ACE inhibitors for lowering blood pressure (such as enalapril and captophl).

G. Prolonged nociceptive pain including without limitation to bone fracture pain, spina! stenosis, and post-surgical pain. V. Visceral pain

The compounds of the invention may be used to treat pain caused by or otherwise associated with any of the following visceral pain conditions. Visceral pain originates from body's viscera, or organs. Visceral nociceptors are located within body organs and internal cavities. The even greater scarcity of nociceptors in these areas produces pain that is usually more aching and of a longer duration than somatic pain. Viscera! pain is extremely difficult to localise, and several injuries to visceral tissue exhibit "referred" pain, where the sensation is localised to an area completely unrelated to the site of injury. Examples of visceral pain include the following.

A. Functional visceral pain

Functional viscera! pain includes, for example, an irritable bowel syndrome and a chronic functional abdominal pain (CFAP), a functional constipation and a functional dyspepsia, a non-cardiac chest pain (NCCP) and a chronic abdominal pain,

B. Chronic gastrointestinal inflammation

Chronic gastrointestinal inflammation includes, for example, a gastritis, an inflammatory bowel disease, e.g., a Crohn's disease, an ulcerative colitis, a microscopic colitis, a diverticulitis and a gastroenteritis; an interstitial cystitis; an intestinal ischemia; a cholecystitis; an appendicitis; a gastroesophageal reflux; an ulcer, a nephrolithiasis, an urinary tract infection, a pancreatitis and a hernia.

C. Autoimmune pain

Autoimmune pain includes, for example, a sarcoidosis and a vasculitis. D. Organic viscera! pain

Organic visceral pain includes, for example, pain resulting from a traumatic, inflammatory or degenerative lesion of the gut or produced by a tumor impinging on sensory innervation. E. Treatment-induced visceral pain Treatment-induced viscera! pain includes, for example, a pain attendant to chemotherapy therapy or a pain attendant to radiation therapy. Vl. Referred pain

The compounds of the invention may be used to treat pain caused by or otherwise associated with any of the following referred pain conditions.

Referred pain arises from pain localized to an area separate from the site of pain stimulation. Often, referred pain arises when a nerve is compressed or damaged at or near its origin, in this circumstance, the sensation of pain will generally be felt in the territory that the nerve serves, even though the damage originates elsewhere. A common example occurs in intervertebral disc herniation, in which a nerve root arising from the spinal cord is compressed by adjacent disc material. Although pain may arise from the damaged disc itself, pain will also be felt in the region served by the compressed nerve (for example, the thigh, knee, or foot). Relieving the pressure on the nerve root may ameliorate the referred pain, provided that permanent nerve damage has not occurred. Myocardial ischaemia (the loss of blood flow to a part of the heart muscle tissue) is possibly the best known example of referred pain; the sensation can occur in the upper chest as a restricted feeling, or as an ache in the left shoulder, arm or even hand.

Pain Reversal An art-accepted model or assay for measuring an analgesic effect of a compound in chronic pain (in particular peripheral neuropathy) is the model known as Kim and Chung 1992, Pain 150, pp 355-363 {Chung model). This model involves the surgical ligation of the L5 (and optionally the L6) spinal nerves on one side in experimental animals. Rats recovering from the surgery gain weight and display a level of general activity similar to that of normal rats. However, these rats develop abnormalities of the foot, wherein the hindpaw is moderately everted and the toes are held together. More importantly, the hindpaw on the side affected by the surgery appears to become sensitive to low-threshold mechanical stimuli and will perceive pain instead of the faint sensation of touch. This sensitivity to normally non-painful touch, called "tactile allodynia", develops within the first week after surgery and lasts for at least two months. The allodynia response includes lifting the affected hindpaw to escape from the stimulus, licking the paw and holding it in the air for many seconds. None of these responses is normally seen in the control group.

To produce the tactile allodynia, rats are anesthetized before surgery. The surgical site is shaved and prepared either with betadine or Novacaine. incision is made from the thoracic vertebra XIII down toward the sacrum. Muscle tissue is separated from the spinal vertebra (left side) at the L4 - S2 levels. The L6 vertebra is located and the transverse process is carefully removed with a small rongeur to expose the L4 - L6 spinal nerves. The L5 and L6 spinal nerves are isolated and tightly ligated with 6-0 silk thread. The same procedure is done on the right side as a control, except no ligation of the spinal nerves is performed.

After a complete hemostasis is confirmed, the wounds are sutured. A small amount of antibiotic ointment is applied to the incised area, and the rat is transferred to the recovery plastic cage under a regulated heat-temperature lamp.

On the day of the experiment, at least seven days after the surgery, typically six rats per test group are administered the test drugs by intraperitoneal (i.p.) injection or oral gavage (p.o.). For i.p. administration, the compounds are formulated in H₂O and given in a volume of 1 mi/kg body weight by injecting into the intraperitoneal cavity. For p.o. administration, the compounds are formulated in H₂O and given in a volume of 1 ml/kg body weight using an 18-gauge, 3 inch gavage needle that is slowly inserted through the esophagus into the stomach. Tactile allodynia is assessed via von Frey hairs, which are a series of fine hairs with incremental differences in stiffness. Rats are placed in a piastic cage with a wire mesh bottom and allowed to acclimate for approximately 30 minutes. To establish the pre-drug baseline, the von Frey hairs are applied perpendicularly through the mesh to the mid-plantar region of the rats' hindpaw with sufficient force to cause slight buckling and held for 6-8 seconds. The applied force has been calculated to range from 0.41 to 15.1 grams. If the paw is sharply withdrawn, it is considered a positive response, A normal animal will not respond to stimuli in this range, but a surgically ϋgated paw will be withdrawn in response to a 1 -2 gram hair. The 50 % paw withdrawal threshold is determined using the method of Dixon, WJ., Ann. Rev. Pharmacol. Toxicol. 20:441 -462 (1980) hereby incorporated by reference. Tactile allodynia is measured prior to and 15, 30, and 60 minutes after drug administration. The post-drug threshold is compared to the pre-drug threshold and the percent reversal of tactile sensitivity is calculated based on a normal threshold of 15.1 grams. Table 1 below indicates the degree of pain reversal obtained in the

Chung model with exemplary compounds of the invention. The tntraperitonial (i.p.) and/or intravenous (iv) administration of the compounds was in doses ranging from 1 μg/kg to 300μg/kg or 3mg/kg PO and the peak percentage of reversal of allodynia was measured at 15, 30 or 60 minutes after administration, as is indicated in the table. Data are expressed as the highest % allodynia reversal (out of 3 time points: 15 min, 30 min, or 60 min. post- drug) with a minimum of a 20% allodynia reversal in the rat Chung model. Comparisons between groups (drug treated vs. saline treated) were made using a two-tailed, 2-sample, unpaired t-test. Compounds that are not shown which were not statistically analgesic following an IP dose of 300 ug/kg, but may still be analgesic. Compounds that do not exhibit significant analgesia at 100 mg/kg are not considered to be analgesic.

TABLE 1

Modes of Administration:

Compounds useful in the methods of the invention may be administered at pharmaceutically effective dosages. Such dosages are normally the minimum dose necessary to achieve the desired therapeutic effect; in the treatment of chromic pain, this amount would be roughly that necessary to reduce the discomfort caused by the pain to tolerable levels. For human adults such doses generally will be in the range of 0,1-5,000 mg/day; more preferably in the range of 1 to 3,000 mg/day, 10 mg to 500 mg/day_t 500 to 1 ,000 mg/day, 1 ,000 to 1 ,500 mg/day, 1 ,500 to 2,000 mg/day, 2,000 to 2,500 mg/day, or 2,500 to 3,000 mg/day. However, the actual amount of the compound to be administered in any given case will be determined by a physician taking into account the relevant circumstances, such as the severity of the pain, the age and weight of the patient, the patient's general physical condition, the cause of the pain, and the route of administration. The compounds are useful in the treatment of pain in a mammal; particularly a human being. Preferably, the patient will be given the compound orally in any acceptable form, such as a tablet, liquid, capsule, powder and the like. However, other routes may be desirable or necessary, particularly if the patient suffers from nausea. Such other routes may include, without exception, transdermal, intraperitonial, parenteral, subcutaneous, intranasal, intrathecal, intramuscular, intravenous and intrarectal modes of delivery. Compositions useful in the method of the invention may further include an excipient. Such an excipient may be a carrier or a diluent; this is usually mixed with the active compound, or permitted to dilute or enclose the active compound. If a diluent, the carrier may be solid, semi-solid, or liquid material that acts as an excipient or vehicle for the active compound. The formulations may also include wetting agents, emulsifying agents, preserving agents, sweetening agents, and/or flavoring agents, if used as in an ophthalmic or infusion format, the formulation will usually contain one or more salt to influence the osmotic pressure of the formulation.

SYNTHETIC METHODS FOR OBTAINING THE COMPOUNDS OF THE

INVENTION, EXPERIMENTAL

The compound of the invention can be synthesized by utilizing the synthetic methods described in the experimental below, or such modifications of the below described experimental methods which will become readily apparent to those skilled in the art in light of the present disclosure. GENERAL

¹H NMR spectra were recorded at ambient temperature with an Avance 300 (Bruker) spectrometer. The compounds were analyzed by reverse phase high performance liquid chromatography (HPLC) using a Waters Autopurification System equipped with a Waters 2525 Pump, a Waters 2696 photodiode array detector, and a XTerra column (Part. No. 186000482, 5 μm, C18, 4,5 x 50 mm).

The HPLC method used was a gradient of 5 % solvent B to 100 % in 7 min. Solvent A was H₂O with 0,05 % TFA and solvent B was CH₃CN with 0.05 % TFA (Method A).

Melting points were measured with a Bϋchi B-545 melting point apparatus and were uncorrected. To isolate reaction products the solvent were removed by evaporation using a vacuum rotatory evaporator, the water bath temperature not exceeding 40 ⁰C. GENERAL SYNTHETIC ROUTES

The compound of the invention can be synthesized by utilizing the synthetic methods described in a general sense immediately below and in more detail in the experimental section of the present application, or by such modifications of the below described general and experimental methods which will become readily apparent to those skilled in the art in light of the present disclosure.

A general synthetic route to the compound of the present invention which are substituted "1-hydroxyi-propyl amines" may lead through the synthesis of the corresponding substituted "3-hydroxyl-propyl amide" compounds, followed by reduction of the carbony! group of the "carboxylic acid amide" moiety with a reducing agent such as lithium aluminum hydride, or like reducing agent.

^NH2 ^R2 LiAIH₄

General Structure 1 General Structure 2

General Synthetic Scheme A

This reaction is illustrated in General Synthetic Scheme A, where, generally speaking, the variables have the meaning described in the Summary Section of the present application for patent. A person of ordinary skill in the art of organic synthesis will nevertheless readily understand that depending on the nature of the substituents designated Ri, R≥ and Ri₀ certain groups may need to be protected for the performance of the reduction step.

The substituted "3-hydroxyl-propyl amide" compounds can, generally speaking, be synthesized as described below in the following Genera! Reaction Scheme 1 and General Reaction Scheme 2.

methyiisocyanoacetate amine 2-Isocyano- 1 -(subst.-amino)ethanone

R^* -CHO strong base "aldehyde" (KOH)

(+l-)-threo /rørts-oxazoline General Structure 1

General Reaction Scheme 1

Thus, in accordance with General Scheme 1 , methyl isocyanoacetate

(or ethyl isocyanoacetate available commercialiy) is reacted with an "amine" which includes the Ri and R₂ groups to provide the 2-isocyanoacetic acid amide derivative shown in General Reaction Scheme 1. Typical examples for the amines used in the reaction are pyrrolidine, piperidine, azetidine, morpholine, 2,5~dihydro-1 H-pyrrole, dialkylamines such as diethylamine, 3- fluoro-, 3,3-difluoro or 3-hydroxy substituted pyrrolidines. The 2- isocyanoacetic acid amide derivative is then reacted in methanol in the presence of base (such as KOH) with an "aldehyde" which includes the R₁₀ group to provide a trans "oxazoline" with high diastereoselectivity (transicis ratios generally > 97:3) as shown in General Reaction Scheme 1 , The trans oxazoiine is then treated in methanol with a strong acid, such as HCI, to open the ring and to provide the tfireo-3-substituted-3-hydroxy-2-amino-propionic acid amide intermediates (with a threo:erythro ratios generally > 97:3) as shown in General Reaction Scheme 1.

Compounds of Formula 1 and or of General Structure 1 , where the amino group of formula NHR₁R₂ is a weaker nucleophile, such as indoline, thiomorpholine and the like, can be made as illustrated in Reaction Scheme 2 for the synthesis of intermediate compounds (±)-f/7reo-2-amino-3-hydroxy-1 - (indoIin-1-yl)-3-(pyridin-4-yl)propan~1-one dihydrochloride Compound 243 and (±)-tf?reσ-2-amino-3-hydroxy-1 -(thiazolidin-3-yl)-3-(pyridin-4-y1)propan-1 - one dihydrochloride Compound 242.

R - Me, ferf-butyl a)

+ trans as ratio >8 2

% yield

(±) threo

Compound 242

a) KOH, MeOH; b) indoline, EDCl, TEA, HOBT, CH₂CI₂ c) HCI (1 Wt) in MeOH d) i. Silica Gel Chromatography n HCI (O 1 M) in /-PrOH e) BOC₂O, NaOH, Dioxane f) Thiazohdine, EDCI, TEA, HOBT, CH₂CI₂, g) Silica Gel Chromatography g) HCI (1 M) in MeOH

Reaction Scheme 2

In Reaction Scheme 2 EDCI stands for 1 -{3-dimethylaminopropyl)- ethylcarbodiimide hydrochloride; HOBT stands for 1 -hydroxybenzotπazoie; BOC₂O stands for di-f-butyl-dicarbonate and TEA stands for triethylamine. Compounds 242 and 243 can be reduced, as illustrated in General Synthetic Scheme A to provide compounds of the invention.

Another general synthetic route may follow in general terms the synthesis of Compound 1 , Compound 2 and Compound 3, specifically described in detail in the experimental section below, modified with such modifications which in light of the present disclosure will become readily apparent to a person of ordinary skill in the art. lsomericaliy pure and/or enantiomerically pure compounds and further derivatives of the 3-substituted-3-hydroxy-2-amino-propionic acid amide intermediates or of the substituted 1 -hydroxy propylamines of the invention are obtained by separation techniques and reactions which, per se, are well known to the synthetic chemist. Some of the typical separation techniques and reactions are generally described below.

Separation of threo and erythro isomers, when both are formed in the reactions leading to the compounds of the invention, can typically be performed by chromatographic methods. The chromatographic separation may occur the level of the substituted 3-hydroxyl-propionic acid amide intermediate compounds or at the level of the substituted 1 -hydroxyl propyl amine compounds of the invention. The more abundantly formed threo isomers can also be converted into the erythro isomers by oxidizing to the ketone level the hydroxy! group in the 3 position of the propanoic acid moiety and subsequently reducing the resulting ketone to the hydroxyl level in the intermediate 3-substituted-3-hydroxy-2- amino-propionic acid amide compounds or in the compounds of the invention.

Separation of enantiomeric mixtures can be performed on Chiralpack columns which are well known in the art.

The amino function in the 2-position of the propyl amine moiety is, generally speaking, more reactive towards acylation and carbamoylation than the hydroxyl group in the 1 position. Therefore, acylated derivatives of the 2- amino function can be prepared by using acyl chlorides such as acetyl chloride and hexanoyl chloride. Or the 1 -hydroxy and 2-amino groups of the compounds of the invention can be acylated in the same reaction. Carbamate derivatives of the 2-amino function can be obtained by using chloroformates, such as benzylchloroformate. A tertiary butyl carbamoyl function or benzyl- carbamoyl function can also serve as a removable protecting group of the 2- amino function.

Alkyiation of the 2-amino function can be performed by condensing the compound bearing the 2-NH₂ group with an aldehyde to obtain a Schiff base intermediate which can be reduced, without isolation, to provide the Λ/-alkyl, arylalkyl or heteroaryl-aikyl compounds of the invention.

DETAILED DESCRIPTION OF THE SYNTHESIS OF PREFERRED COMPOUNDS (EXPERIMENTAL)

Preparation of D-f/7reo-2-amino-3-morpholino-1 -phenylpropan-1 -ol dihvdrochloride Compound 4. (R)-Methyl 1 -((S)-1 -phenylethyl)aziridine-2-carboxylate EBE 06044B.

To solution of methyl 2,3-dibromopropionate (25 mL, 198 mmol) in toluene at 5 ⁰C was added triethylamine (55 mL, 0.39 mmol) in toluene (100 mL). After stirring for 5 min (S)-(I )-phenethylamine (25 mL, 198 mmol) in toluene (100 mL) was added dropwise. The suspension was refluxed for 3 h and allowed to cool down, filtered and the volatiles were evaporated under reduced pressure to give a residue that was purified by column chromatography (950 g of silica gel) with a gradient of 0-20 % EtOAc in cyclohexane to yield to (S)-methy! 1-((S)-1-phenylethyl)aziridine-2-carboxylate EBE 06044A as a yellow oil (17.31 g, 43 % yield) and (fi)-methyl 1 -((S)-I - pheny!ethy!)aziridine~2-carboxylate EBE 06044B as a yellow oi! (15.14 g, 37 % yield).

EBE 06044B

MW: 205.3; Yield EBE 06044B: 37 %; Yellow Oil. Yield: EBE 06044A: 43 %,

Yellow Oil. R_/: EBE 06044A = 0.5; R/: EBE 06044B = 0.35 (EtOAc:cyclohexane =

25:75).

¹H-NMR (CDCI₃₁) EBE 06044A: 1.47 (d, 3H, J= 6.6 Hz, CH₃), 1.60 (d, 1 H, J =

6.4 Hz, CH)₁ 2.13 (d, 1 H₁ J= 2.6 Hz), 2.21 (dd, 1 H, J= 3.2 Hz, J= 6.4Hz),

2.54 (q, 1 H, J= 6.6 Hz), 3.75 (s, 3H, OCH₃) 7.23-7.40 (m, 5H₁ ArH). 1H-NMR (CDCI₃, δ): EBE 06044B: 1.46 (d, 3H₁ J= 6.6 Hz, CH₃), 1.79 (d, 1 H,

J= 6.6 Hz, CH), 2.08 (d, 1 H, J= 3.11 Hz, 6.6 Hz), 2.34 (dd, 1 H₁ J = 3.1 Hz, J =

1.0 Hz), 2.56 (q, 1 H, J= 6.6 Hz)₁ 3.67 (s, 3H, OCH₃) 7.24-7.36 (m, 5H, ArH).

¹³C-NMR (CDCi₃, δ): EBE 06044B: 23.5, 35.0, 36.9, 52.2, 69.8, 126.5, 127.2,

128.5, 143.6, 171.1. HPLC: Method A, detection at 254 nm, EBE 06044B RT = 6.11 min, peak area 92.9 %.

((R)-I -((S)-1 -Phenylethyl)aziridin~2-yl)methanol EBE 06046.

A 250 mL round bottom flask was charged with anhydrous THF (10OmL) and LiAIH₄ (2.77 g, 73.1 mmol). While the suspension is stirred at 0 ⁰C, a solution of (S)-methyl 1 -((S)-1 -phenylethyl)aziridine-2-carboxylate EBE 06044B (10.0 g, 48,7 mmol) in THF (50 mL) was added dropwise over 20 min The dropping funnel was washed with THF (2 x 3 rnL) and allowed to react 20 min at 0⁰C. Maintaining the reaction mixture at 0⁰C, a solution of KOH (10 %, 20 mL) was added dropwise for 20 min (caution the reaction is exothermic). The mixture was stirred for 0.5 h at 25 ⁰C and the white precipitate removed by filtration through a celite pad that was washed with diethyl ether (30 mL). The combined organic filtrates were washed with NaH₂PO₄ and the aqueous layer was extracted with Et₂O (3 x 30 mL), The combined organic phase were dried with Na₂SO₄ and concentrated to give ((H)-I -((S)-1 -phenylethy!)aziridin- 2-yl)methanol EBE 06046 as a white solid (10.4 g, 90 % yield).

EBE 06046

MW: 177,2; Yield: 90 %; White Solid; Mp (⁰C): 37.7.

¹H-NMR (CDCI₃, δ): : 1.43 <d, 3H, J = 6.6 Hz₁ CH₃), 1.49 (d, 1 H₁ J= 6.5 Hz, CH), 1.65-1.71 (m, 1 H, CH), 1.92 (d, 1 H₁ J = 3.5 Hz, NCH), 2.26 <s, 1 H₅ OH), 2.53 (q, 1 H, J = 6.6 Hz, NCH), 3.32-3.37 (m, 1 H, OCH₂), 3.56 (m, 1 H, OCH₂), 7.23-7.35 (m, 5H₁ ArH), 1³C-NMR (CDCI₃, δ): : 22.9, 31.4, 39.3, 62.5, 69.4, 126.6, 127.3, 128.6, 144.5.

(fi)-1 -((S)-1 -Phenylethyi)aziridine-2-carbaidehyde EBE 06048 A three neck, 250 mL round bottom flask was equipped with a low temperature thermometer and two (2) equalizing dropping funnels. One of these was connected to a nitrogen line and charged with a solution of ((H)-I - ((S)-I -ρhenylethy!)aziridin-2-y!)methanol EBE 06046 (7.0 g, 39.5 mmol) in CH₂CI₂ (75 mL), the other was charged with a solution of DMSO (9.25 g, 118.5 mmol) in CH₂CI₂ (11 mL). To a solution of oxalyl chloride (7.5 g, 59.3 mmol) in CH₂CI₂ (90 mL) under N₂ at -78 ⁰C, the DMSO solution was added dropwtse during 20 min and stirred for 20 min, EBE 06046 (7.0 g, 39.5 mmol) in CH₂CI₂ (75 mL) was added dropwise over 50 min. then the dropping funnel was charged with DIEA (42,6 mL, 237 mmol) in CH₂CI₂ (10 mL) and the reaction mixture was stirred for 30 min at -45°C. The DIEA solution was added over 5 min with the reaction mixture at -78 °C and the reaction was allowed to warm to room temperature. The reaction mixture was washed with H₂O (3 x 50 mL), dried over MgSO₄, filtered, evaporated. The crude product obtained was purified by column chromatography on silica with a gradient of 0-20 % [v/v] EtOAc in cyclohexane to give (R)-1 -((S)-1 -phenylethyl)aziridine~ 2-carbaidehyde EBE 06048 as a yellow oil (5.59 g, 81 % yield).

EBE 06048

MW: 175.2; Yield: 81 %; Yellow Oil,

R_/: EBE 06048: 0.3 (EtOAc:cyclohexane = 20:80).

¹ H-NMR (CDCi₃, δ): : 1.47 ( d, 3H₁ J = 6.6 Hz, CH₃), 1.94 (d, 1 H, J = 6.7 Hz, NCH₂), 2,08 (dt, J = 2.9 Hz₁ J = 6.4 Hz, NCH), 2.37 (d, 1 H₁ J = 2.6 Hz₁ NCH₂),

2.61 ( q, 1 H, J = 6.6 Hz₁ NCH), 7.20-7,38 (m, 5H, ArH), 8.92 (d, 1 H, J = 6.2

Hz).

¹³C-NMR (CDCI₃, δ): : 22.7, 32.1 , 43.2, 68.1 , 125.5, 126.5, 127.6, 142.4,

198.7.

(fl)-Phenyl((fl)-1 -((S)-1 -ρhenylethyl)aziridin-2-yl)methanol EBE 06066.

To a solution of bromobenzene (4.93 g, 31.4 mmol) in THF 125 mL under nitrogen at - 78 ⁰C was added f-BuLi (1.7 M in pentane, 50 mL). The mixture was stirred for 0.5 h at room temperature. The mixture was cooled down to -78 ⁰C and a solution of (R)-I -((S)-1 -phenylethyl)aziridine-2- carbaldehyde EBE 06048 (2.5 g, 14.3 mmol) in THF (16.7 mL) at -78 ⁰C was added dropwise. The reaction mixture was treated with H₂O (20 mL), the organic layer was separated and the aqueous phase was extracted with EtOAc. The combined organic layers were dried over MgSO₄, filtered and concentrated in vacuo to give a residue that was purified by column chromatography using a gradient of 0-20 % [v/v] EtOAc in cyclohexane to give (fl)-phenyl((fl)-1 -((S)-1 -phenytethyl)aztridin-2-yl)methanol EBE 06066 (3.13 g, 86 % yield).

EBE 06066

MW: 253.3; Yieid: 86 %.

R_f : = 0.3 (EtOAc:cyciohexane = 20:80).

¹H-NMR { CDCI₃, δ): : 1.47 (d, 3H₁ J = 6.6 Hz, CH₃), 1.57 (d, 1 H, J = 6.5 Hz,

CH), 1.79 (dt, 1 H₁ J= 3.5 Hz₁ J - 8.7 Hz, CH), 2.04 (d, 1 H, J = 3.5 Hz, OCH), 2.35 <bs, 1 H, OH), 2.53 (q, 1 H, J = 6.5 Hz, CH), 4.23 (d, 1 H, J = 5.7Hz, OCH),

7.07-7.13 (m, 2H, ArH), 7.16-7.20 (m, 3H, ArH), 7.24-7.34 (m, 5H, ArH).

¹³C-NMR (CDCI₃, δ): : 22.4, 32.0, 44.6, 69.4, 74.1 , 125.8(2xC), 126.9 (2xC),

127.3, 127.6, 128.2 (2xC), 128.7 (2xC), 142.0, 144.2.

[Q]²²D = - 71.53 (C = 0.59, CHCl₃).

D-f/?reo-2-((S)-1 -Phβnylethylamino)-3-morpholino-1 -phenylpropan-1 -ol dihydrochloride Compound 5

To a solution of (fl)-phenyl((fl)-1 -((S)-1 -phθnylethyl)aziridin-2- yl)methanol EBE 06066 (1.5 g, 5.92 mmol) in CH₃CN (19 mi_) at RT was added iodotrimethylsilane (3.55 g, 17.8 mmol). The solution was stirred for 2 h and morpholine (1.032 g, 11.84 mmol) was added. After 2 h at reflux, the reaction mixture was treated with HCI (1 M) to reach pH = 1 and stirred for 10 min. After a slow addition of NaHCO₃ to reach pH = 9, the product was extracted with EtOAc, dried over Na₂SO₄, filtered to give after evaporation a crude brown oil that was purified by column chromatography using a gradient of 0-20% [v/v] MeOH in EtOAc to give D-#7reo-2-((S)-1-phenylethylamino)-3~ morpho!ino-1 -phenylpropan-1 -ol EBE 06068A (0.831 g, 42 %) as a pale brown solid. To a solution of D-f/7r©o-2-((S)-1 -phenylethy1amino)-3- morpholtno-1 -phenylpropan-1 -ol EBE 06068A {0 .100 g, 0.294 mmol) in ethanol (1 ml_) was added a solution of HCI (0.8 M, 0,816 ml_) in EtOH. Evaporation of the volatiles afforded to D-tf?reo-2-((S)-1 -pheny!ethylamino)-3- morpholino-1 -phenylpropan-1 -ol dihydrochloride Compound 5 as white soiid (0.125 g, 100 %).

Compound 5 MW: 412.37; Yield: 42 %; White Solid; Mp (⁰C): 157.2 (dec). Hf. 0.3 (MeOH:EtOAc = 20:80) EBE 06068A.

¹H-NMR (CD₃OD₁ δ):_. :1.19 (t, 2H₁ J = 7.0 Hz, NCH₂), 1.71 (d, 3H, J = 6.8 Hz, CH₃), 3.45 (m, 2H₁ J = 7.1 Hz, NCH₂), 3.62 (q, 2H, J = 7.1 Hz₁ N-CH₂), 3.97 (t, 4H, J = 4.5 Hz, OCH₂), 4.06 (m, 1 H₅ CH-N), 4.75 (q, 1 H, J = 6.8 Hz, CH-N), 5.21 (d, 1 H, J = 5.1 Hz, CH-O), 7.44-7.56 (m, 10H, ArH). MS-ES! m/z (% rel. Int.): 341.1 ([MH]⁺, 20).

¹³C-NMR (CD₃OD₁ δ): : 24.4, 54.5 (2xC), 55.5, 55.9, 60.O₁ 67.0 (2xC), 75.6,

126.3 (2xC), 126.5 (2xC), 127.0, 127.1 , 128.1 (2xC), 128.5 (2xC), 142.2,

145.3.

HPLC: Method A, detection at 254 nm, Compound 5 RT = 4.41 min, peak area 99 %.

T/?reσ-2-Amino-3-morpholino-1 -phβnylpropan-1 -ol dihvdrochioride Compound 4.

To a solution of D-f/7reo-2-((S)-1 -phenyiethylamino)-3-morpholino-1 - phenyipropan-1 -ol EBE 06068A (0.400 g, 1.17 mmol) in MeOH (6 mL) at RT was added acetic acid (0.133 mL, 2.35 mmol). The reaction vessel was flushed with nitrogen and Pd(OH)₂ (25 % weight, 0.150 g) was added. The nitrogen atmosphere was exchanged with hydrogen using three cycle of vacuum and hydrogen addition using a balloon of hydrogen. After stirring for 16 h under hydrogen the reaction mixture was filtrated through celite to give EBE 06070A the acetate salt of (2R)-amino-3-morphoIin-4-yl-(1 /^:?)-phenyl- propan-1 -ol (0.279 g, 98 % yield). To as solution of EBE 06070A the acetate salt of (2/?)-amino-3-morpholin-4-yl-(1 f?)-phenyl-propan-1 -ol (0.100 g, 0.338 mmol) in ethanol (1 ml_) was added a solution of HC! (0.8 M, 0.930 rnl_) in EtOH. Evaporation of the volatiles afforded to D-f/7røo2-amino-3-morpholino- 1 -phenylpropan-1 -ol di hydrochloride Compound 4 (0.104 g, 100 % yield) as an off white solid. (Adapted from Shin, S-H.; Han, E.Y.; Park, C.S.; Lee, W.K.; Ha, H. -J. Tetrahedron Asymmetry, 2000, 11, 3293-3301 ).

Compound 4

MW: 309.23; Yield: 99 %; Off White Solid; Mp (⁰C): 183.4. 1H-NMR (CD₃OD, δ): : 3.30-3.77 (m, 6H₁ CH₂N), 3.92-4.05 (m, 4H, CH₂O),

4.05-4.16 (m, 1 H₅ CH), 4.85-4.98 (m, 1 H₅ CH), 7.35-7.60 (m, 5H, ArH).

¹³C-NMR (CD₃ODJ: 53.2, 58.3, 58.5 (2xC), 64.9 (2xC), 72,6, 128.0 (2xC),

130.2 (2xC), 140.3.

MS-ESI m/z (% rel. int.): 237.1 (100, [MH]⁺). HPLC: lsocratic 10 % CH₃CN in H₂O (pH 10, [NH₄OH] = 5 mM), detection UV

254 nm, Compound 4 RT = 6.63 min, peak area 97.3 %.

[α]²² _D = - 10.7 (c = 1.00, MeOH).

Preparation of Benzyl L-f/?feo-1 -hvdroxy-3-morphotino-1 -phenylpropan-2- ylcarbamate hydrochloride Compound 1.

Benzyl (S)-3-hydroxy-1 -oxo-1 -phenylpropan-2-ylcarbarnate TTA 0801 OB. To a stirred solution of Z-L-Ser-OH (6.00 g, 25.08 mmol) in 32 mL of anhydrous THF at 0⁰C under nitrogen was added dropwise 1 M phenylmagnesium bromide in THF (32 mL, 200 mmol). (The symbol Z designates a benzylcarbamoyl group). The mixture was stirred 15 h at RT under nitrogen. A solution of 2 M HCI (100 mL) was slowiy added at 0°C and the mixture was partitioned between ethyl acetate (750 mL) and acidic water. The organic layer was washed with water (2 x 20 mL), 1 N aqueous sodium bicarbonate (2 x 20 mL), brine (2 x 20 mL) and dried over MgSO₄. After removing ethyl acetate by evaporation at 30-35 ⁰C, the crude product (4.50 g, 60 % yield) was cristallized in a mixture of ethy! acetate:hexane = 25 mL:20 mL to give benzyl (S)-3-hydroxy-1 -oxo-1 -phenylpropan-2-ylcarbamate TTA 0801 OB as a white solid (1.40 g, 20 % yield).

TTA 08010B

MW: 299.32; Yield: 20 %; White Solid; Mp (⁰C): 106.5.

B_f : 0.75 (CH₂C^MeOH = 9:1 ).

¹H-NMR (CDCI₃, δ): : 2.78 (s, 1 H₁ OH), 3.85-3.93 (m, 1H₁ CH₂O), 4.00-4.09 (m, 1 H₁ CH₂O)₅ 5,14 (s, 2H, ArCH₂O), 5.40 (t, 1 H₁ J = 3.3 Hz, CH), 6.17 (d,

1 H₁ J = 6.4 Hz₁ NH), 7.35 (s, 5H, ArH), 7.49 (t, 2H, J = 7.60 Hz, ArH), 7.62 (t,

1 H, J = 7.1 Hz, ArH), 8.99 (t, 2H, J = 7.6 Hz, ArH).

¹³C-NMR (CDCl₃, δ): : 58,3, 64.6, 67.3, 128.1 , 128.3, 128.6, 128.7, 129.0,

134.1 , 136.0, 156.6, 196.6. MS-ESi m/z (% rel. Int.): 300.1 ([MH]⁺, 5), 256.1 (100).

HPLC: Method A, detection UV 254 nm, TTA 0801 OB RT = 5.40 min, peak area 98.5 %.

[α]²² _D = - 5.8 (c = 1 .00, MeOH). Benzyl L-threo-Λ ,3-dihydroxy-1 -phenylpropan-2-ylcarbamate TTA 08012.

To a stirred solution of benzyl (S)-3-hydroxy-1-oxo-1-phenylpropan-2~ ylcarbamate TTA 0801 OB (1.40 g, 4,70 mmol) in 28 ml_ of anhydrous THF at - 78 ⁰C under nitrogen was added slowly dropwise 1 M DiBAL-H in hexane (18.8 ml__f 18.80 mmoi). The mixture was stirred 2 h at -78 ⁰C then 1.5 h at RT, A solution of 2 M HCi (35 mL) was slowly added at -20 ⁰C and the mixture was partitioned between ethyl acetate (750 mL) and acidic water. The organic phase was washed with water (2x20 mL), brine (2x20 mL) and dried over MgSO₄. After removing ethyl acetate by evaporation at 30-35 ⁰C, the crude product was purified by column chromatography on silica (CH2Cl2:MeOH = 98:2 to 97:3) to give benzyl L-tf?reo-1 ,3-dihydroxy-1 -phenylpropan-2- ylcarbamate TTA 08012 as a white solid (1.1O g, 78 % yield).

TTA 08012

MW: 301.34; Yield: 78 %; White Solid; Mp (⁰C): 102.5.

R,: 0.30 (CH₂CI₂:MeOH = 95/5).

¹H-NMR (CDCI₃, δ): : 3.08 (t, 1 H, J = 5.0 Hz₅ OH), 3.59 (d, 1 H, J = 3.1 Hz, OH)₅ 3.64-3.78 (m, 2H, CH₂O), 3.80-3.89 (m, 1 H₁ CH), 4.95 (s, 2H, ArCH₂O),

5.57 (d, 1 H, J = 8.3 Hz, NH), 7.17-7.38 (m, 10H, ArH).

¹³C-NMR (CDCl₃, δ): : 57.5, 63,6, 66.9, 73.8, 126.0, 127.8, 127.9, 128.1 ,

128.5, 128.6, 136.2, 141 .0, 156.9.

MS-ESI m/z (% rel. Int.): 302.0 ([MH]⁺, 5); 132.0 (100). HPLC: Method A, detection UV 254 nm, TTA 08012 RT = 5.00 min, peak area

99.5 %.

[α]²² _D = + 39.4 (c=1.00, MeOH). Benzyl threo- 1 -hydroxy-3-morpholino-1 -phenylpropan-2-yicarbamate hydrochioride Compound 1.

To a stirred solution of benzyl L-f/?reo-1 ,3-dihydroxy-1 -phenylpropan-2- ylcarbamate TTA 08012 (1.0O g, 3.30 mmol) in 13 mL of pyridine at -10 ⁰C was added dropwise methanesulfonyl chloride (0.27 mL, 3.50 mmoi}. The mixture was stirred 6 h at 20 ⁰C under nitrogen. Pyridine was removed by evaporation at 30-35 ⁰C and the residue was partitioned between ethyl acetate (250 mL) and 0.1 N HCI (20 mL). The organic phase was washed with water (20 mL), brine (20 mL), dried over MgSO₄ and evaporated to give after drying L-threo-1 -hydroxy-3-methanesu!fonyl-1 -phenylpropan-2-ylcarbamate TTA 08014 (1.25 g , 65% yield).

To a stirred solution of crude benzyl L-tfireo-1 -hydroxy-3-rnethanesulfonyl-1 - phenylpropan-2-ylcarbamate TTA 08014 (1.25 g, 3.30 mrnol) in 6 mL of DMF at RT was added morpholine (1.2 mL, 13.20 mmol). The mixture was stirred 15 h at 50 ⁰C under nitrogen. DMF was evaporated and the residue was partitioned between ethyl acetate (250 mL) and 1 N aqueous sodium bicarbonate (20 mL). The organic phase was washed with water (20 mL), brine (20 mL) and dried over MgSO₄. After evaporation the crude product was purified by column chromatography on silica (CH2Cl2:MeOH = 98:2 to 97:3) to give benzyl L-tf?reo-1-hydroxy-3-morpholino-1 -phenylpropan-2-ylcarbamate as an oil (380 mg, 31 % yield). The hydrochloride salt was obtained from 100 mg of the free base in diethylether at 0⁰C using a solution 0.3 M HCI in diethylether. The precipitate was filtered and dry to give benzyl L-threo-λ - hydroxy-3-morpholino-1 -phenylpropan-2-ylcarbamate hydrochloride Compound 1 as a white solid (70 mg, 65 % yield).

Compound 1 MW: 406.90; Yield: 20 %; White Solid; Mp (⁰C): 144.5.

R,: 0.40 (CH₂CI₂:MeOH = 95:5).

¹H-NMR (CD₃OD₁ δ): : 3.14-3.77 (m, 6H₁ CH₂N), 3.70-4.07 (m, 4H, CH₂O)₁

4.30-4.33 (m, 1 H, CH), 4.90-5.06 (m, 3H, CH₁ ArCH₂O), 7.20-7.43 (m, 1 OH, ArH).

¹³C-NMR (CD₃OD, δ): : 51.2, 51.8, 53.2, 59.3, 63.2, 66.3, 72.5, 125.8, 127.2,

127.3, 127.5, 127.8, 127,9.

MS-ESl m/z (% rel. Int.): 371.0 ([MH]⁺, 100).

HPLC: Method A, detection UV 254 nm, Compound 1 RT = 4.40 min, peak area 96.5 %.

[αpo = +13.9 (c = 1 .00, MeOH).

Preparation of f/7reo-2-amino-3-morpholino-1 -phenylpropan-1 -ol dihydrochlohde Compound 2.

To a stirred solution of benzyl L-f/?reo-1 -hydroxy-3-morpholino-1- phenylpropan-2-ylcarbamate (Compound 1 , 0.26 g, 0.70 mmol) in 20 ml_ of

MeOH at RT was added Pd-C 10 % (140 mg). The mixture was satured with hydrogen and stirred for 24 h at RT under hydrogen atmosphere (balloon).

The catalyst Pd-C 10% was removed by filtration on celite and the solution was evaporated. The crude product was purified by column chromatography on silica (CH₂CI₂:MeOH:NH₄OH = 79:20:1 to 75:20:5) to give L-tf7røo-2-amino-

3-morpholino-1 -phenylpropan-1 -ol as an oil (100 mg, 60 % yield). The hydrochloride salt was obtained from 83 mg of the free base in diethylether at

0 °C using 0.3 M HCI in diethylether. After precipitation in diethylether, filtration and drying L-tf7røo-2-amino-3-morpholino-1 -phenylpropan-1 -ol dihydrochioride Compound 2 was obtained as a white solid (80 mg, 74 % yield).

Compound 2

MW: 309.23; Yield: 44 %; White Solid; Mp (⁰C): 166.4-170.9.

R_f:0.20 (CH₂CI₂MeOH = 9:1 ). 1H-NMR (CD₃OD, δ): : 3.30-3.77 (m, 6H₁ CH₂N)₅ 3.92-4.05 (m, 4H, CH₂O),

4.05-4.16 (m, 1 H, CH), 4.85-4.98 (m, 1 H, CH), 7.35-7.60 <m, 5H, ArH).

¹³C-NMR (CD₃OD, δ): : 53.1 , 54.9, 58.5, 64.8, 72.6, 127.2, 128.0, 130.2,

140.3.

MS-ESl m/z (% rel. Int.): 237,0 ([MH]⁺, 100). HPLC: Method A, detection UV 254 nm, Compound 2 RT = 0.90 min, peak area 98.0 %.

[α]²² _D = +10.8 (c = 1.00, MeOH), free base: [α]²² _D = - 6.1 (c = 0.25, CHCI₃).

Preparation of benzyl L-fftreo-1 -acetoxy-3-morphoiino-1 -phenylpropan-2- ylcarbamate hydrochloride Compound 3. Benzyl L-threo-λ -acetoxy-3-morpholino-i -phenyipropan-2-ylcarbamate hydrochloride Compound 3.

To a stirred solution of benzyl L-fftreo-1 -hydroxy-3-morpho!ino-1 - phenylpropan-2-ylcarbamate hydrochloride (Compound 1 , 0.510 g, 1.25 mmol) in 30 ml_ of CHCI₃ at RT were added slowly triethylamine (700 μl_, 5.00 mmol) and acetyl chloride (145 μl_, 2.00 mmol). The mixture was stirred 10 h at RT under nitrogen and partitioned between a mixture of ice-water (20 ml_) and CH₂Cb (100 mL). The organic layer was washed with brine (20 ml) and dried over MgSO₄. After evaporation the crude product was purified by column chromatography on silica (CH₂CI₂:MeOH = 99.5:0.5 to 98:2) to give benzyl L- ifΛreo-1 -acetoxy-3-morpholino-1 -phenyipropan-2-ylcarbamate as an oil (0.420 g, 81 % yield).

The hydrochloride salt was obtained from 45 mg of the free base in diethylether at 0 ⁰C using a solution of 0.3 M HCI in diethylether. The precipitate was filtered and dry to give benzyl L-tf7reσ-1 -acetoxy-3-morpholino- 1 -phenylpropan-2-y!carbamate hydrochloride Compound 3 as a white solid

(40 mg, 82 % yield).

Compound 3

MW: 448.94; Yield: 66 %; White Solid; Mp (⁰C): 69.9,

Bf. 0.70 (CH₂CI₂:Me0H = 95:5). 1H-NMR (CD₃OD, δ): : 2.10 (s, 3H, CH₃), 3.14-3.44 (m, 4H, CH₂N), 3.70-4.00

(m, 4H, CH₂O), 4.51 -4.53 (m, 1 H, CH), 4.90-5.13 (m, 2H, ArCH₂O), 5.89 (d,

1 H₁ CH), 7.28-7.48 (m, 10H₁ ArH).

¹³C-NMR (CD₃OD, δ): : 20.8, 52.0, 52.6, 59.7, 64.6, 68.0, 76.5, 127.7, 129.0,

129.2, 129.5, 129,8, 137.9, 158.7, 171.3. MS-ESi m/z <% rel. Int.): 413.0 ([MH]⁺, 100).

HPLC: Method A, detection UV 254 nm, Compound 3 RT = 4.70 min, peak area 98,5 %.

Preparation of DL-f/?reσ-2-(Decanamido)-1 -(4-methoxyphenyl)-3-(pyrroiidin-1 - vOpropyl decanoate Compound 10. 2-!socyano-1-(pyrrolidin-1-yl)ethanone BLE 04098.

To stirred and cooled (0⁰C) methyl isocyanoacetate (96 % technical grade, 5.0 g, 47.8 mmol) was slowly added in 0.75 h pyrrolidine (6,5 mL, 78 mmol). The mixture was stirred for 1.5 h with continued cooling and then concentrated. The resulting oil was co-evaporated twice from CH₂C!₂:hexane to remove residual pyrrolidine. 2-lsocyano-1 -(pyrrolϊdin-1 -y!)ethanone BLE

04098 was obtained as a yellow solid (6.85 g, 98 % yield) and used in the next step without purification.

BLE 04098 MW: 138.17; Yield: 98 %; yellow solid; Mp (⁰C) = 73,9, 1H-NMR (CDCI₃, δ): : 1.81 -2.08 (m, 4H, 2xCH₂), 3.35-3.45 (m, 2H₁ -NCH₂), 3.50-3.60 (m, 2H₁ -NCH₂J₁ 4.23 <s, 2H, CH₂CO). 7rans-(4,5-dihydro-5-(pyridin-3-yl)oxazol-4-yi)(pyrro!idiri-1-yl)methanone BLE 0411OB, frans-(4,5-Dihydro-5-(4-methoxyphenyl)oxazol-4-yl)(pyrroiidin-1 -yl)methanone SLA 07074.

To a stirred and cooled (O⁰C) solution of potassium hydroxide (0.37 g, 6,57 mmol) in methanol (30 mL) was added a mixture of 4-methoxy- benzaldehyde (0.88 mL, 7.23 mmol) and 2-isocyano-1-(pyrrolidin-1- yl)ethanone BLE 04098 (1.0 g, 6.57 mmol). The solution was stirred 4 h with continued cooling and then concentrated. The residue was partitioned between ethyl acetate and water. The organic layer was combined with additional ethyl acetate extracts, washed with aqueous sodium chloride and dried over MgSO₄. Concentration afforded a crude product as a glassy solid. Flash chromatography over silica (ethyl acetate) yielded to fraπs-(4,5-dihydro- 5~(4-methoxyphenyl)oxazol-4-yi)(pyrrolidin-1 -y!)methanone SLA 07074 as a pale yellow solid (1.2 g, 90.5 %).

SLA 07074

MW: 274.32; Yield: 90,5 %; pale yellow solid; Mp (⁰C): 91.2,

FV 0,30 (EtOAc).

¹H-NMR (CDCI₃, δ): : 1.75-2.08 (m, 4H, 2xCH₂), 3.40-3.58 (m, 3H, CH₂N),

3.52 (S₁ 3H, CH₃O), 3.88-3.98 (m, 1 H, CH₂N), 4,59 (dd, 1 H, J= 7.6 Hz, J = 2.2 Hz, CH-N), 6.06 (d, 1 H, J = 7.6 Hz, CH-O)₁ 6.90 (d, 2H, J = 8.7 Hz, ArH), 7.01 (d, 1 H₁ J = 2.2 Hz, CH=N), 7.25 (d, 2H, J = 8.7 Hz, ArH). MS-ESI m/z (% rel. Int.): 275.1 ([MH]⁺, 10), 247.1 (100). HPLC: Method A₁ detection UV 280 nm, SLA 07074 RT = 5.2 min, peak area 92 %.

DL-tf?reo-2-Amino-3-hydroxy-3-(4-methoxyphenyl)-1 -(pyrrolidin-1 -yl)propan-1 - one hydrochloride SLA 07078. To a stirred solution of frans-(4,5-dihydro-5-(4-methoxyphenyi)oxazol-

4-yl)(pyrrolidin-1 -yl)methanone SLA 07074 (1.61 g, 5.93 mmol) in methanol (13 mL) was added hydrochloric acid (1mL). After heating at 50 ⁰C for 3 h the mixture reaction was concentrated and the resulting yellow oil was co- evaporated twice with ethyl acetate before solidifying. Trituration (ethyl acetate) and drying afforded DL-tf)reo-2-amino-3-hydroxy-3-(4- methoxyphenyl)-1 -(pyrrolidin-1 -yl)propan-1 -one hydrochloride SLA 07078 as a white solid (1.64 g, 93 %).

(+/-)

SLA 07078 MW: 300.78; Yield: 93 %; white Solid; Mp (⁰C): 177.0.

¹H-NMR (CD₃OD₅ δ): : 1.32-1.50 (m, 1 H, CH₂), 1.50-1.88 (m, 3H₅ CH₂), 2.15- 2.28 (m, 1 H, CH₂N), 3.15-3.42 (m, 4H, 2XCH₂N)₁ 3.79 (s, 3H, CH₃O), 4.06 (d, 1 H₁ J = 9.2 Hz, CH-N), 4.78 (d, 1 H, J = 9.2 Hz, CHO), 6.94 (d, 2H, J = 8.5 Hz, ArH)₁ 7.34 (d, 2H, J = 8.5 Hz, ArH). 1³C-NMR (CD₃OD, δ): : 24.8, 26.6, 47.2, 47.6, 55.9, 59.6, 73.9, 115.0 (2xC), 128.9 (2xC)_t 132.5, 161.7, 166.4.

DL-ff7reo-2 -Amino- 1 -(4-methoxyphenyl)-3-(pyrrolidin-1 -vPpropan-1 -oi Compound 9.

To a stirred suspension of DL-f/7reo-[5-(4-methoxy-phenyi)-4,5-dihydro- oxazol-4-yl]-pyrrolidin-1 -yl-methanone SLA 07078 (1.61 g, 5.35 mmol) in tetrahydrofuran (200 mL) under nitrogen atmosphere was slowly added, in two portions, lithium aluminium hydride (1.22 g, 32.12 mmol) at 0 ⁰C. The mixture reaction was stirred at RT for 17 h, and then quenched by a slow, dropwise addition of water (50 ml_). The white suspension was then concentrated to remove THF and taken back up in a mixture of 300 mL CH₂Cb and 1 N aqueous hydrochloric acid (50 mL). The aqueous layer was basified to pH = 10-11 by a slow addition of 1 N aqueous sodium hydroxyde. The organic layer was removed, combined with additional CH₂Ci₂ extracts (4 x 200 mL) and dried over MgSO₄, filtered and evaporated. The crude product was purified by column chromatography on silica (CH₂CI₂IMeOHiNH₃ = 94:05:01 ). After evaporation and drying, DL-_/7reo-2-amino-1 -(4- methoxyphenyl)-3-(pyrrolidin-1 -yi)propan-1 -ol Compound 9 was obtained (0. 62 g, 46 %) as a pale yellow solid.

OH

Compound 9

MW: 250.34; Yield: 46 %; Pale Yellow Solid; Mp (X): 77.7. R/: 0.35 (CH₂CI₂:MeOH:NH₃ = 94:05:01).

¹H-NMR (CDCI₃, δ): : 1.65-1.87 (s, 4H, 2xCH₂), 2.40-2.90 (m, 9H, CH₂N, NH₂ & OH)₁ 3.11 -3.17 (m, 1 H, CH_:N), 3.81 (s, 3H, CH₃O), 4.61 (d, 1 H, J= 3.8 Hz, CH-O), 7.89 (d, 2H, J = 8.6 Hz, ArH), 7.26 (d, 2H, J = 8.5 Hz, ArH). 1³C-NMR (CDCI₃, δ): : 23.6 (2xC), 54.5_» 54.7 (2xC), 55.3, 60.1 , 75.9, 113.6, 127.4, 134.4, 158.8.

MS-ESI m/z (% rel. Int.): 251.1 ([MH]+, 100).

DL-^reo2-(Decanamido)-1 -(4-methoxyphenyl)-3-(pyrrolidin-1 -yl)propyl decanoate Compound 10.

To a stirred solution of DL-f/?reo-2-amino-1 -(4-methoxy-phenyl)-3- pyrrolidin-1 -yl-propan-1 -ol Compound 9 (0.15 g, 0.60 mmol) in dichloromethane (10 mL) were added Λ/-hydroxysuccinimide (0.07 g, 0.60 mmol), triethylamine (0.10 mL, 0.63 mmol) and decanoyl chloride (112 μL, 0.54 mmol) under nitrogen atmosphere. The mixture reaction was stirred at RT for 22 h and partitioned between methylene chloride and 1 N aqueous sodium hydroxide. The organic layer was dried over MgSO₄, filtered and evaporated. The crude product was purified by column chromatography on silica (CH₂Ci₂: MeOH = 95:05). DL-fftreo-2-(Decanamido)-1 -(4- methoxyphenyl)-3-(pyrrolidin-1 -yI)propyl decanoate Compound 10 was obtained as a white oil (0,104 g, 31 %).

Compound 10 MW: 558.84; Yield: 40 %; White Oil. R^: 0.35 (CH₂CI₂:MeOH = 95:05),

¹H-NMR (CDCI₃, δ): : 0.88 (t, 6H, J = 0.7 Hz, 2xCH₃), 1.26 (s, 14H, 7xCH₂), 1.57-1.59 (m, 4H, 2XCH₂), 1.80 (m, 4H, 2xCH₂), 2.10-2.50 (m, 5H, CH₂), 2.65- 2.76 (m, 5H, CH₂), 3.79 (s, 3H, CH₃O), 4.54 (m, 1 H, CH-N), 5.89 (d, 1 H, J = 6.2 Hz, CH-O), 6.16 (d broad, 1 H, J = 8.8 Hz, NH)₁ 6.85 (d, 2H, J = 8.7 Hz, ArH), 7,24 (d, 2H, J = 8.7 Hz, ArH).

MS-ESI m/z (% rel. int.): 559.5 ([MH]+, 100).

HPLC: Method A, detection UV 280 nm, Compound 10 RT = 6.99 min, peak area 96.4 %,

Λ/-(DL-ff?reo-1 -Hydroxy- 1 -(4-methoxyphenyl)-3-(pyrrolidin-1 -yl)propan-2- vQpalmitamide or DL-tfireo-4-MeQ-P4 Compound 1 1.

To a stirred solution of DL-fftreo-2-amino-1 -(4-methoxyphenyl)-3- (pyrrolidin-1-yl)propan-1 -ol Compound 9 (015 g, 0.60 mmol) in dichloromethane (10 mL) were successively added Λ/-hydroxysuccinimide (0.07 g, 0.60 mmol), triethylamine (0.100 mL, 0.63 mmol) and palrnitoyl chloride (0.15 g, 0.54 mmol) under nitrogen atmosphere. The mixture reaction was stirred at RT for 17 h and partitioned between methylene chloride and 1 N aqueous sodium hydroxide. The organic layer was dried over MgSO₄, filtered and evaporated. The crude product was purified by column chromatography on silica (CH₂Cl₂: MeOH = 95:05). Λ/-(DL-tf)røo-1 -Hydroxy-1 -(4- methoxyphenyl)-3-(pyrrolidin-1 -yl)propan-2-yl)palmitamide Compound 11 was obtained as a white solid (0. 117 g, 40 %).

Compound 11

MW: 488.75; Yield: 40 %; White Solid; Mp (⁰C): 82.3.

Rf. 0.35 (CH₂CI₂:MeOH = 95:05). 1H-NMR (CDCI₃,.: 0.88 (t, 3H, J = 7.0 Hz₁ CH₃), 1.22-1.33 (m, 16H₁ SxCH₂),

1.47-1.54 (rn, 2H₅ CH₂), 1.81 (m, 4H, 2xCH₂), 2.09 <t, 2H, J = 7.0 Hz, COCH₂),

2.60-2.80 (m, 4H, 2xCH₂), 2.84 (d, 2H, J = 5.1 Hz, CH₂), 3.80 (s, 3H, CH₃O),

4.23 (m, 1 H, CH-N), 5.00 (d, 1 H, J = 2.2 Hz, CH-O), 5.90 (d, 1 H, J = 7.4 Hz,

NH), 6.87 (d, 2H, J= 8.7 Hz, ArH), 7.24 (d, 2H, J= 8.7 Hz, ArH). 1³C-NMR (CDCi3, δ): : 14.1 , 22.7, 23.6, 25.6, 29.1 , 29.3, 29.4, 29.5, 29.7,

29.7, 31.9, 36.8, 52.3, 55.2, 57.8, 75.4, 1 13.7 (2x0), 127.0 (2xC), 133.1 ,

158.9, 173.6.

MS-ESI m/z (rel. int.): 489.2 ([MH]+, 100).

HP LC: Method A, detection UV 280 nm, Compound 11 RT = 6.55 min, peak area 96.4 %.

DL-#7røp2-Amino-1 -(2,3-dihydrobenzorάif 1 ,4ldioxin-6-yl)-3-(pyrrolidin-1 ^■ yl)propan-1 -ol Compound 6.

fra/7S-(4,5-Dihydro-5-(2,3-dihydrobenzo[6][1 ,4]dioxin-6-yl)oxazol-4~ y!)(pyrroiidin-1 -yl)methanone BLE 04100. To a stirred and cooled (0⁰C) solution of potassium hydroxide (0.43 mg, 7.60 mmol) in MeOH (6.5 mL) were added successively 1 ,4-benzodioxan-6- carboxaldehyde (1.31 g, 7.96 mmol) and 2-isocyano-1 -(pyrrolidin-1 - yl)ethanone BLE 04098 (1.0 g, 6.57 mmol). The solution was stirred 3 h at O⁰C and then concentrated. The residue was partitioned between EtOAc (100 mL) and water. The organic layer was combined with 2 additional EtOAc extracts (2 x 100 mL), washed with brine, dried over MgSO₄, filtered and evaporated. Concentration afford to a crude product which was purified by column chromatography on silica (EtOAc) to yield, after evaporation and drying, to ?ra/is-4,5-dihydro-5-(2,3-dihydrobenzo[£>][1 ,4]dioxin-6-yl)oxazol-4- yl)(pyrrolidin-1 -yl)methanone BLE 04100 as a colourless oil (1.76 g, 89 % yield).

BLE 04100

MW: 440.49; Yield: 89 %; colourless oil.

¹H-NMR (CDCl₃, δ): : 1.75-2.10 (m, 4H, 2xCH₂), 3.40-3.59 (m, 6H, 3xCH₂N), 3.85-4.00 (m, 1 H, CHN), 4.26 (s, 4H, CH₂O), 4.59 (dd, 1 H, J = 7.5 Hz, J = 2.2 Hz, CH-N), 6.00 (d, 1 H, J = 7.5 Hz, CH-O), 6.75-6.90 (m, 3H, ArH), 7.00 (d, 1 H, J= 2.2 Hz, CH=N).

DL-f/?reo-2-amιno-3-(2,3-dihydrobenzorάiri ,4ldioxin-6-yl)-3-hydroxy-1 - (pyrrolidin-1 -yl)propan-1 -one hydrochloride Compound 12.

To a stirred solution of fra/7s-4,5-dihydro-5-(2,3- dihydrobenzo[£)][1 ,4]dioxin-6-yl)oxazol-4-yl)(pyrrolidin-1 -yl)methanone BLE 04100 (1.74 g, 5.77 mmol) in methanol (15 mL) was added hydrochloric acid (1 mL). After heating at 50⁰C for 3h the mixture reaction was concentrated and the resulting yeliow oil was co-evaporated twice with ethyl acetate before solidifying. Trituration (ethyl acetate) and drying afforded DL-f/7reo-2-amino-3- (2,3-dihydrobenzo[_lb][1 _!4]dioxin-6-yl)-3-hydroxy-1-(pyrrolidin-1 -yl)propan-1 - one hydrochloride Compound 12 as a white solid (1.85 g, 95 %).

5 (^+/">

Compound 12

MW: 328.79; Yield: 95.0 %; White Solid; Mp (⁰C): 176.2. 1H-NMR (CD₃OD₁ 5): : 1.42-1.58 (m, 1 H₁ CH₂), 1.58-1.70 (m, 1 H₁ CH₂), 1.70- 1.88 (m, 2H, CH₂), 3.20-3.45(m, 4H, N-CH₂), 4.06 (d, 1 H, J = 9.1 Hz, CH-N),0 4.25 (S₅ 2H, CH₂), 4.75 (d, 1 H₁ J= 9.2 Hz, CH-O), 4.89 (s, 2H, CH₂), 6.82-6.95 (m, 3H, ArH).

¹³C-NMR (CD₃OD, δ): : 24.9, 26.7, 47.3, 47.6, 59.5, 65.7, 73.6, 116.4, 118.3, 120.3, 133.7, 145.1 , 145.6, 166.4. ^ DL-f/?reo-2-Aιτιino-1 -(2,3-dihvdrobenzorfrH ,41dioxin-6-yl)-3-(pyrrolidin-1 - vQpropan-1 -ol Compound 6.

To a stirred suspension of frans-(4,5-dihydro-5-(4- methoxyphenyl)oxazol-4-yl)(pyrrolidin-1 -yl)methanone SLA 07080 (1.79 g, 5.44 mmol) in THF (220 mL) was slowly added at 0 °C, in two portions, UAIH40 (1.28 g, 33.7 mmol). The mixture was stirred at RT for 3.5 h and quenched by a slow addition of water at 0 ⁰C (350 mL). The white suspension was concentrated to remove THF and taken back in a mixture of CH₂CI₂ (300 mL) and 1 N aqueous HCI (50 mL). The aqueous layer was basified to pH = 10-11 by slow addition of 1 N aqueous NaOH. The organic layer was removed; two more extracts were combined and dried over MgSO4, filtered and evaporated. Concentration afforded to a crude product as a yellow oil. This material was purified by column chromatography on silica (CH₂CI₂:MeOH:NH4OH 20% = 94:5:1 ) to led to DL-^reo-2-amino-1 -(2,3-dihydrobenzo[d][1 ,4]dioxin-6-yl)-3- (pyrrolidin-1 -yi)propan-1 -oi Compound 6 (0.705 g, 46,5 % yield) as a near colorless gum.

Compound 6

MW: 278.35; Yield: 46.5 %; Colorless Gum, R_f: 0.20 (CH₂Cl₂:MeOH:NH₄OH 20 % = 94:5:1 ).

¹H-NMR (CDCI₃, δ): : 1.70-1.85 (m, 4H, 2XCH₂), 2.40-2.70 (m, 6H₁ 3xCH₂N-)_: 3.05-3.15 (m, 1 H, CH-N), 4.25 (s, 4H, CH₂O), 4.55 (d, 1 H, J = 2.2 Hz, CH-O), 5.30 (s, 1 H, -OH), 6.75-6.90 (m, 3H, ArH).

N-(DL-threo-1 -(2,3-dihvdrobenzordiM ,41dioxin-6-yl)-1 -hydroxy-3-(pyrrolidin-1 - vi)propan-2-yl)decanamide Compound 7.

To a stirred solution of DL-tfϊreo-2-amino-1 -{2,3- dihydrobenzo[b][1 ,4]dioxin-6-yl)-3-(pyrrolidin-1 ~yl)propan-1 -ol BLE 04104 (0.186 g, 0.67 mmol) in 10 mL CH2CI2 were added, in order, N- hydroxysuccinimide (0.081 g, 0,70 mmol) in 2 mL CH2CI2, triethyiamine (112 μL, 0.80 mmol) and decanoyl chloride (125 μL, 0.60 mmol). The mixture was stirred overnight at RT and then partitioned between CH₂CI₂ and 1 N aqueous sodium hydroxide. The organic layer was dried over MgSO₄, filtered and evaporated and the residue obtained was purified by column chromatography on silica (CH₂CI₂:MeOH = 95:5). A white solid Λ/~(DL-tfjrøo-1 -(2,3- dihydrobenzo[£>][1 ,4]dioxin-6-yl)-1 -hydroxy-3-(pyrro!idin-1 -yl)propan-2- yl)pa!mitamide Compound 7 was obtained (126 mg, 43.5 % yield).

Compound 7

MW: 516.76; Yield: 43.5 %; White Solid; Mp (⁰C): 84.6.

R_/: 0.40 (MeOH:CH₂CI₂ = 10:90). 1H-NMR (CDCI₃, δ): : 0.88 (t, 3H, J = 6.7 Hz, CH₃), 1.12-1.39 (m, 12 H), 1.40-

1.60 (m, 2H, CH2), 1.72-1.90 (m, 4H₁ 2xCH2), 2.10 (t, 2H, J = 6.7 Hz₁ CH2),

2.55-2.90 (m, 6H), 4.13-4.30 (m, 1 H, CH-N), 4.24 (s, 4H₁ CH2N), 4.91 (d, 1 H₁

J = 3.3 Hz, CH-O), 5.90 (d, 1 H₅ J = 7.4 Hz, NH), 6.75-6.88 (m, 3H, ArH), OH not seen. 1³C-NMR (CDCl₃, δ): : 14.1 , 22.7, 23.6 (2xC), 25.6, 29.1 , 29.3, 31.9, 36.8,

52.3, 55.1 (2xC), 57.7, 64.3 (2xC), 75.2, 77.2, 115.0, 117.0, 1 18.9, 134.4,

142.8, 143.4, 173.5, 174.8.

MS-ESI m/z (% rel. Int.): 433.1 ([MH]⁺, 100).

HPLC: Method A, detection UV 280 nm, Compound 7, RT = 5.2 min, peak area 96.2 %.

NADL-threo-Λ -(2,3-DihvdrobenzorάI1 ,4ldioxin-6-yl)-1 -hydroxy-3-(pyrroiidin-1 - yl)propan-2-yl)paimitamide Compound 8.

To a stirred solution of DL-tf7reo-2-amino-1 -(2,3- dihydrobenzo[έ>][1 ,4]dioxin-6-yl)-3-(pyrrolidin-1 -yl)propan-1 -ol BLE 04104 (0.158 g, 0.57 mmol) in 10 mL CH₂Cb were added, in order, N- hydroxysuccinirnide (0.068 g, 0.59 mmol) in 2 ml CH2CI2, triethylamine (95 μL, 0.68 mmol) and palmitoyi chloride (155 μL, 0.511 mmol) in 3 mL CH₂CI₂. The mixture was stirred overnight at RT and then partitioned between CH₂CI₂ and 1 N aqueous sodium hydroxyde. The organic layer was purified by column chromatography on silica using as eluent CH₂CI₂:MeOH = 95:5. A white solid Λ/~(DL-tf?reo-1 -(2,3-dihydrobenzo[fo][1 ,4]dioxin-6-yl)-1 -hydroxy-3- (pyrrolidin-1 -yl)propan-2-yi)palmitamide Compound 8 was obtained (148 mg, 50.4 % yield).

Compound 8

MW: 516.7; Yield: 50.4 %; White Solid; Mp (⁰C): 66.4.

R,: 0.50 (MeOH:CH₂CI_£ = 10:90).

¹H-NMR (CDCI₃, δ): : 0.88 (t, 3H, J = 6.7 Hz, CH₃), 1.15-1.35 (m, 24 H), 1.45- 1.58 (m, 2H, CH₂), 1.75-1.90 (m, 4H, 2xCH₂), 2.10 (t, 2H, J = 7.4 Hz₁ CH₂),

2.61 (s, 1H, OH), 2.52-2.72 (m, 4H), 2.72-2.92 (m, 2H), 4.15-4.22 (m, 1 H, CH-

N), 4.24 (s, 4H₁ CH₂N)₁ 4.92 (d, 1 H, J = 3.3 Hz, CH-O), 6.08 (d, 1 H₁ J = 7.4

Hz, NH)₅ 6.75-6.90 (m, 3H, ArH).

MS-ESI m/2 (% rel. Int.): 517.2 ([MH]⁺, 100). HPLC: Method A, detection UV 280 nm, Compound 8 RT = 6.60 min, peak area 97.2 %.

Preparation of PL-tf7reo2-Amino-1 -(pyridin-4-yl)-3-(pyrrolidin-1 -yl)propan-1 -ol

Compound 46. Tra/7S-(4,5-dihydro-5-(pyridin-3-yl)oxazol-4-yl)(pyrrolidin-1 -yl)methanone BLE

04110B.

A genera! method D for oxazolines formation is illustrated by the preparation of BLE 04110B: To a stirred and cooled (0⁰C) solution of potassium hydroxide (0.55 g, 9.80 mmol) in methanol (10 mL) were added a mixture of 3-pyridine carboxaldehyde (1.03 mL, 10.84 mmol) and 2-isocyano-

1 -(pyrrolidin-1 -yl)ethanone BLE 04098 (1.50 g, 10.86 mmol). The solution was stirred 3 h at 0⁰C and then concentrated. The residue was partitioned between ethyl acetate (100 mL) and water. The organic layer was combined with two additional ethyl acetate extracts (2x100 mL), washed with aqueous sodium chloride and dried over MgSO₄, filtered and evaporated. Concentration afforded a crude product which was purified by column chromatography on silica (CH₂Ci₂: MeOH = 98:2) to yield to frar?s-(4,5-dihydro- 5-(pyridin-3-yl)oxazol-4~yiXpyrrolidin~1-yϊ)rnethanone BLE 0411OB (0.95 g, 39 %) as a pale yellow ρa!e solid.

BLE 04110B MW: 245.28; Yield; 39 %; Yellow Pale Solid; Mp (⁰C): 107.0.

¹H-NMR (CDCI₃, δ): : 1.78-2.10 (m, 4H, 2xCH₂), 3.40-3.61 (m, 3H, CH₂N), 3.90-4.04 (m, 1 H, CH₂N), 4.59 (dd, 1 H, J = 7,7 Hz, J = 2,2 Hz, CH-N), 6.21 (d, 1 H₅ J = 7.7 Hz₁ CH-O), 7.04 (d, 1 H₁ J = 2.2 Hz₁ 0-CH=N), 7.33 (m, 1 H₅ ArH), 7.64 (m, 1 H, ArH), 8.59 (d, 2H, J = 2.8 Hz, ArH). 1³C-NMR (CDCl₃₁ δ): : 24.2, 26.0, 46.4, 46.6, 75.7, 79.3, 123.7, 133.5, 135.3, 147.6, 149.9, 155.2, 166.2. frans-f4.5-Dihydro-5-(pyridin-4-yl)oxazol-4-yl)(pyrrolidin-1 -yl)methanone Compound 19.

Compound 19 was prepared in accordance with method D using pyridine-4-carbaldehyde (1.88 mL, 19.76 mrnol), KOH (1.01 g, 18.00 mmol) in methanol (18 mL) and 2-isocyano-1 -(pyrroIidin-1 -y!)ethanone BLE 04098 (2.73 g, 19.76 mmol). The residue was partitioned between ethyl acetate (200 mL) and water (150 mL). The organic layer was combined with additional ethyl acetate extracts (2 x 150 mL), washed with aqueous sodium chloride (2 x 150 mL) and dried over MgSO₄, filtered and evaporated. 7rans-(4,5-dihydro- 5-(pyhdin-4-yl)oxazol-4-yl)(pyrrolidin-1 -yi)methanone Compound 19 was obtained as a white solid (4.32 g, 98 % yield).

Compound 19

MW: 245.28; Yield: 98 %; White Solid; Mp (⁰C) = 69.2. R_/: 0.65 (MeOH:CH₂CI₂ = 10:90). 1H-NMR (CDCI₃, δ): : 1.78-2,06 (m, 4H₅ 2xCH₂), 3.44-3,60 (m, 3H, CH₂N), 3.90-4.01 (m, 1 H₁ CH₂N,), 4.52 (dd, 1 H, J - 7.9 Hz₁ J = 2.2 Hz, CH-N)₁ 6.19 (d, J = 7.9 Hz₁ 1 H, CH-O), 7.03 (d, 1 H₁ J = 2.2 Hz, N=CH-O), 7.24 (dd, 2H, J = 4.5 Hz₁ J = 1.5 Hz, ArH), 8.61 (dd, 2H, J = 4.5 Hz, J = 1.5 Hz, ArH).

A general method for the acidic hydrolysis of oxazolines (Method E) is illustrated in the preparation of Compound 20 which is a substituted propionic acid amide and is made from the oxazoline intermediate BLE 04110B which can be prepared in accordance with General Synthetic Scheme 1.

BLE 04110B

DL-fftreo2-Amino-3-hvdroxy-3-(pyridin-3-yl)-1 -(pyrrolidin-1 -yl)propan-1 -one dihvdrochloride Compound 20.

To a solution of frans-(4,5-dihydro-5-(pyridin~3-yl)oxazol-4- yl)(pyrrolidin-1 -yl)methanone BLE 04110B (0.932 g, 3.80 mmol) in methanol (10 mL) was added hydrochloric acid 37 % (1.2 mL). After heating (50 °C) the mixture for 2.25 h the reaction mixture was concentrated and the crude product was coevaporated twice with ethyl acetate. After trituration with ethyl acetate, filtration and drying DL-tf?reo-2-amino-3-hydroxy-3-(pyridin-3-yl)-1- (pyrrolidin-1 -yl)propan-1 -one dihydrochioride Compound 20 was obtained as a white solid (1.10 g, 94 % yield).

2.HCI

Compound 20

MW: 308.2; Yield; 94 %; White Solid; Mp (⁰C): 123.4.

¹H-NMR (CD₃OD, δ): : 1.65-2.00 (m, 4H, 2xCH₂), 2.82-3.11 (m, 1 H₁ -CH₂N), 3.30-3.57 (m, 2H, CH₂N), 3.57-3.77 (m, 1 H, CH₂N)₁ 4.54 (d, 1 H, J = 5.3 Hz,

CH-N), 5.38 (d, 1 H, J = 5.3 Hz₁ CH-O), 8.15 (dd, 1 H, J = 7.6 Hz₁ J = 5.0 Hz,

ArH), 8.68 (d, 1 H₁ J = 7.6 Hz₅ ArH), 8.89 (d, 1 H₁ J = 7.6 Hz, ArH), 8.96 (s, 1 H,

ArH).

¹³C-NMR (CD₃OD₁): 24.9, 26.9, 47.7, 48.2, 58.1 , 69.6, 128.7, 141.5, 141.6, 143.1 , 146.5, 165.4.

DL-jfftreo-2-Amino-3-hvdroxy-3-(pyridin-4-yl)-1 -(pyrrolidin-1 -yl)propan-1 -one dihvdrochloride Compound 22.

Compound 22 was prepared following method E with trans-{4,5- dihydro-5-(pyridin-4-yl)oxazoi-4-yl)(pyrrolidin-1 -yl)methanone Compound 19 (0.750 g, 3.07 mmol), hydrochloric acid 37 % (1.0 mL) and methanol (10 mL).

After 3.0 h at 50 ⁰C and work-up DL-tf7røo-2-amino-3-hydroxy-3-(pyridin-4-yl)-

1 -(pyrrolidin-1 -yl)propan-1 -one dihydrochioride Compound 22 was obtained as a white solid (0.935 g, 99 %).

Compound 22

MW: 308.28; Yield: 99 %; White Solid; Mp (⁰C): 117.0. 1H-NMR (CD₃OD, δ): : 1.75-2.03 (m, 4H_S 2xCH₂), 2.93-3.08 (m, 1H₁ CHN), 3.32-3.75 (m, 3H, 2xCH₂), 4.54 (d, 1 H, J = 5.9 Hz, CH₁N), 5.40 (d, 1 H, J = 5.9 Hz, CH-O), 8.21 (d, 2H, J = 5,8 Hz, ArH), 8.94 (d, 2H, J= 5.8 Hz, ArH). MS-ESI m/z (% rel. int.): 236.1 ([MH]+, 17), 219 (25), 148 (100), HPLC: Method A, detection UV 254 nm, Compound 22 RT = 0.8 min, peak area 96.3 %. DL-f/ireo-2-Amino-i -(pyridin-4-vO-3-(pyrrolidin-1 -yl)propan-1 -ol Compound 46. To a stirred suspension of DL-#7reo-2-amino-3-hydroxy-3-(pyhdin-4-yI)- 1 ~(pyrro!idin-1 -yl)propan-1 -one dihydrochloride Compound 22 (0.86 g, 2.80 mmo!) in tetrahydrofuran (108 ml_) under nitrogen atmosphere was slowly added, in two portions, lithium aluminium hydride (0.64 g, 16.82 mmol) at 0 ⁰C. The mixture reaction was stirred at RT for 20 h and quenched by a slow, dropwtse addition of 2 N aqueous sodium hydroxyde (8.4 mL, 6 eq). The yellow precipitate was filtered. The organic layer was washed by water (80 mL) and the organic layer was removed and combined with additional ethyl acetate extracts (4 x 200 mL) and dried over MgSO₄, filtered and evaporated. The crude product was purified by column chromatography on silica

(CH₂CI₂:MeOH:NH₃ = 94:05:01 ), After evaporation and drying DL-threo-2- amino-1 -(pyridin-4-yl)-3-(pyrroiidin-1 -yi)propan-1 -ol Compound 46 was obtained (0. 075 g, 12 %) as a pale yellow solid.

OH

Compound 46 MW: 221.30; Yield: 12 %; Pale Yellow Solid. R_/: 0.35 (CH₂CI₂:Me0H:NH₃ = 90:08:02),

¹H-NMR (CD₃OD, δ): : 1.60-1.80 (m, 4H, 2xCH₂), 2.30-2.80 (m, 6H, 3xCH₂N), 3.14-3.19 (m, 1 H, CH₁NH₂), 4.68 (d, 1 H, J = 3.0 Hz, CH-O), 7.30 (d, 2H₁ J = 6.0 Hz₁ ArH), 8.55 (d, 2H, J = 6.0 Hz, ArH).

¹³C-NMR (CD₃OD, δ): : 23.5 (2xC), 54.1 , 54.7 (2xC), 60.1 , 74.5, 121.4 (2xC), 149.5 (2xC)_; 152.1.

MS-ESi m/z (rel. int.): 222.1 ([MH]+, 100), 205.0 (80), 189.0 (45), 151.0 (70), 134.0 (42), 121.9 (100), 107.9 (40).

Claims

WHAT IS CLAIMED IS:

1 , The use of a compound in the manufacture of a medicament for treating a condition selected from the group consisting of neuropathic pain, inflammatory pain, headache pain, somatic pain, visceral pain, and referred pain, wherein the compound has the following structure

wherein R₁ is H or alky! of 1 to 6 carbons,

R₂ is H, alkyl of 1 to 6 carbons or the Ri and R₂ groups together with the nitrogen form a saturated or unsaturated 4, 5, 6 or 7 membered ring that optionally includes one or two heteroatoms independently selected from N, O and S, said 4, 5, 6 or 7 membered ring optionally being substituted with a halogen or with an alkyl group having 1 to 6 alkyl groups; R₃ is independently selected from H, alkyl of 1 to 20 carbons, aryl or heteroaryl, aryl-alkyl or heteroaryi-alkyl wherein the alkyl moiety is has 1 to 4 carbons, cycloalkyl of 3 to 6 carbons, said aryl or heteroary! groups being optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 6 carbons, or R₃ is CO-R₇ or CO-O-R₇ wherein R₇ is H, alkyl of 1 to 1 to 20 carbons, benzyl, alkyl of 1 to 20 carbons substituted with and NH₂ group, with a NHCOOalkyl or with an NH-COaikyl group wherein the alkyl group has one to 6 carbons, or R₇ is aryl, heteroaryl, aryl-alkyl or heteroaryl-alkyl wherein the alkyl moiety is branched or unbranched and has 1 to 4 carbons, said aryl or heteroaryl groups being optionally substituted with 1 to 3 groups independently selected from the group consisting of halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons and thioxy of 1 to 6 carbons; R₄ is H, alkyl of 1 to 6 carbons or CO-R₈ wherein R₈ is alkyl of 1 to 6 carbons; the wavy lines represent bonds connected to carbons having R or S configuration, and

R₁₀ is selected from the groups of formulas (i) and (H)

(i) (ϋ) wherein the ^* indicates the carbon atom to which the remaining moiety of the molecule is attached; R₅ and R₆ independently are H, alkyi of 1 to 6 carbons, halogen, alkoxy of 1 to 6 carbons or the R₅ and R₆ groups together with the atoms to which they are attached jointly form a carbocyclic or a heterocyclic ring, the carbocyclic ring having 5 or 6 atoms in the ring, the heterocyclic ring having 5 or 6 atoms in the ring and 1 to 3 heteroatoms independently selected from N, O and S, and said carbocyclic or heterocyclic ring jointly formed by R₅ and R₆ being optionally substituted with 1 to 6 R₉ groups wherein R₉ is independently selected from halogen, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, or a pharmaceutically acceptable salt of said compound; with the proviso: that when Ri₀ has formula (ii) then the claim does not include compounds wherein R₄ is hydrogen and Ri and R₂ jointly with the nitrogen form a morpholin or a pyrrolidin ring and wherein R₅ and R₆ both are H or one of R₅ and R₆ is OCH₃ and the other is H,

2. The use according to claim 1 , wherein R₁₀ represents the formula (i).

3. The use according to claim 1 , wherein R₁₀ represents the formula (ii).

4. The use according to claim 2, wherein the compound has the formula

DL- threo wherein R₅ and Re are independently selected from H, alkyl and aikoxy and R₄ is H or CO-R₈ or a pharmaceutically acceptable salt of said compound, 5. The use according to Claim 4, wherein the compound has the formula

OH

DL- threo or a pharmaceutically acceptable salt of said compound.

6. The use according to claim 3, wherein the compound has the formula

Dl-threo wherein R₃ is CO-R₇ or CO-O-R₇, R₄ is CO-R₈ and R₅ and R₆ are independently selected from H, alkyl of 1 to 6 carbons and aikoxy of 1 to 6 carbons or any other pharmaceutically acceptable salt of said compound.

7. The use according to Claim 6, wherein the compound has the formula

HCi l-threo or any other pharmaceutically acceptable salt of said compound.

8. The use of a compound in the manufacture of a medicament for treating a condition selected from the group consisting of neuropathic pain, inflammatory pain, headache pain, somatic pain, viscera! pain, and referred pain, wherein the compound has the following structure

OH

or any other pharmaceutically acceptable salt of said compound. 9. The use of a compound in the manufacture of a medicament for treating a condition selected from the group consisting of neuropathic pain, inflammatory pain, headache pain, somatic pain, visceral pain, and referred pain, wherein the compound has the following structure

2. HCl L-threo or any other pharmaceutically acceptable salt of said compound.